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Drug delivery systems have gained significant interest in the pharmaceutical industry for the 
treatment of various diseases, such as cancer, neurological and genetic disorders, and viral 
infections. While many of the designed compounds show great potential by having a high affinity 
to their specific molecular targets in vitro, their potency is limited due to their failure to deliver 
molecules across the cell membrane. Their transporting ability is affected by their characteristics 
such as poor water solubility, charge, hydrophobicity, and size. Thus, there is a necessity for the 
design of new molecular transporters that can efficiently deliver molecules across the semi-
permeable plasma membrane. Peptides have been studied rigorously as a drug delivery system due 
to several factors such as their capability to bind specific cell surface receptors, their ability to 
permeate through the hydrophobic core of the plasma membrane, and the ease of making small 
adjustments to the amino acid sequence.  Furthermore, the major concern of targeting of a single 
molecular marker of the cancerous cell is tumor heterogeneity and rapid mutations. It is vital to 
focus on an intrinsic property of the diseased cell, such as the extracellular pH of cancer cells. For 
example, in malignant tumors, the extracellular pH can approximately be one pH unit lower than 
normal cells. A pH-triggered membrane peptide can be used to target cells with altered 
extracellular pH. Therefore, we have designed the acidity triggered rational membrane (ATRAM) 
peptide as a novel class of pH-sensitive peptides to address these applications. Here we established 
that the ATRAM peptide interacts in a pH-sensitive manner with membranes of liposomes and 
cultured cancer cells.  ATRAM also interacts reversibly with human serum albumin suggesting 
that while the peptide can use albumin as a carrier in the blood stream, explaining its ability to 
avoid immediate proteolysis in vivo, it will still target and transfer to the cell membrane. Moreover, 
we tried to fine-tune the pH responsiveness of ATRAM. The subsequent single N-terminal 
modifications to the peptide sequence resulted in diverse interactions with cancer-mimic lipid 
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1.1. Prevalent problems with current anticancer drugs 
Some of the most promising anticancer drug candidates are also the most hydrophobic. While 
these anticancer drugs show great potential in vitro, their use in clinical trials has been less than 
unsuccessful due to low solubility and off-target side effects (1-3).  Most of the drugs are either 
weakly acidic or weakly basic, resulting in poor aqueous solubility (4).  The low solubility in 
aqueous media reduces the clinical utility of the drug due to low bioavailability and, consequently, 
suboptimal drug concentrations at the site of action. Bioavailability is a measure of absorption and 
represents the portion of the administered dose to enter the vascular system to access the site of 
action (4).  Less water-soluble drugs need increased doses in order to reach therapeutic 
concentrations at the site of action.  Hydrophobic drugs therefore require solubilizing agents, 
which are mostly organic solvents, in order to be able to be absorbed by cancer cells.  (5, 6).  
However, these solubilizing agents not only reduce the potency of the drugs but also may have 
undesirable toxic side effects such as causing hypersensitivity, neurotoxicity, and nephrotoxicity 
(5). 
Camptothecin, doxorubicin, and paclitaxel are successful anticancer drugs (7).  While in vitro 
studies have shown that these drugs are effective against different cancers, such as breast, bladder, 
melanoma, and lung, they require mixing with solubilizing agents, such as a mixture of  the 
detergent Tween 80 or Kolliphor EL (a castor oil derivative formerly known as Cremophor EL), 
and ethanol, in order to be used in humans.  Such formulation results in decreased potency of the 
drug and increased  toxic side effects (5), which limit the efficacy of these and many other 
anticancer drugs. For instance, doxorubicin is a widely used chemotherapeutic; however, besides 
the adverse effects of nausea, alopecia and neutropenia, its dose-dependent cardiotoxicity limits 
the drug’s clinical usage (8). All these effects are the result of different mechanisms, such as the 
3 
 
immune system being hyper-activated, reduced progenitor cell repair, and inhibition of growth 
factors. The main mechanism for the cardiotoxicity is believed to be due to iron oxidation and 
oxygen free radical generation (8).  Peripheral nerves can also be affected by commonly used 
chemotherapeutic agents (9, 10).  Paresthesia, loss of sensory function, and neuropathic pain can 
result from use of these cytotoxic drugs. In the case of paclitaxel, neurotoxic side effects can be 
dose-limiting (11).  Paclitaxel stabilizes microtubules, which consequently arrests mitosis and 
leads ultimately to cell death.  However, neurons are also prone to being affected by the drug. The 
loss of microtubule dynamic instability is thought to be the cause for the toxicity to microtubule-
rich axons (11, 12).  Another important limitation with the use of current chemotherapeutic drugs 
is that they lack selective cytotoxicity between cancer cells and healthy cells.  Anticancer drugs 
are not able to selectively destroy cancerous cells without also harming the normal cells that are 
in proximity of the target cells,  resulting in damaged organs (13).   
To address the important issue of off-target cytotoxicity associated with the use of hydrophobic 
anticancer drugs, many different approaches have been developed to improve selectivity of the 
drug and to reduce the cytotoxic effects on healthy tissues.  The development of novel delivery 
systems for these insoluble drugs without the use of organic solvents has received significant 
attention (14, 15).  Liposomes have been studied as a potential vesicular drug delivery system as 
they can encapsulate the drug, and potentially be targeted to tumor cells.  However, the physical 
degradation, leakage and fusion of liposomes, can lead to untimely drug release (16).  
Nanoparticles (NPs) have been used as a vehicle for these insoluble drugs using direct targeting to 
tumors, which overcomes the insolubility issue and off-target toxicity (17, 18).  However, many 
of the different nanoparticle systems result in side effects too; for instance, pulmonary 
inflammation and platelet aggregation have been observed (14). 
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As a non-particulate alternative, cell penetrating peptides (CPPs), which are short peptides 
capable of moving across the plasma membrane (19) may serve as vehicles to transport small 
molecule drugs.  However, like the drugs themselves, many of the CPPs do not specifically target 
tumor cells.   While these peptides seem highly effective and nontoxic in vitro, only some are able 
to distinguish the target cancer cells from healthy cells in culture due to the loss of anionic lipid 
asymmetry attracts the positive charges of the peptide (15). However, in animal models the 
specificity is still low and cause toxicity, preventing effective clinical translation (20).  Similar to 
CPPs, antimicrobial peptides (AMPs) are short cationic peptides that can enter the cell by 
disrupting the membrane (21).  Certain AMPs also have the ability to translocate cargo across the 
cell membrane.  Thus, AMPs have been explored and developed as a potential means to deliver 
therapeutics to fight infectious diseases but also cancer as anticancer peptides (ACPs) (22).  Factors 
that slow down the use of ACP in drug development are their low resistance to proteolytic 
cleavage, and some ACPs also have low selectivity, thus resulting in high off target toxicity (23).  
Additionally, concerns of AMPs’ sequences being close to natural human AMPs have arisen as 
they may compromise or trigger natural defense mechanisms (23).  As current drugs and their 
potential transporters are non-selective, it is imperative to develop a therapeutic strategy that 
lowers off-target side-effects by targeting a cancer-specific biomarker.  
 
1.2. Targeted cancer therapy 
Targeted therapies are used in the treatment of numerous diseases, including cancer (24-26).  
These therapies focus on a molecular target in the diseased cell, a biomarker.  For example, tumor 
cells are hypermetabolic, produce elevated levels of cell-surface receptors, extracellular growth 
factors, and enzymes as they play crucial roles in tumor progression (1, 27).  Many therapies, such 
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as therapeutic monoclonal antibodies, will target these molecular biomarkers (28); however, 
successful targeting of specific proteins is limited by tumor heterogeneity.  
Heterogeneity between tumors at different stages of metastasis is caused by genetic instability 
(29).  Mutational frequencies of genes differ between the many tumor types due to the distinct 
signaling pathway specific to each cellular context (30).  Intertumor heterogeneity occurs when 
there is genetic and phenotypic variation between tumors of different tissues and between different 
people (30).  Moreover, cancer cells from the same origin might have different genetic variation 
(intratumor heterogeneity) (31). This is due to branched tumor evolution (32), wherein a new clone 
is unable to outcompete the precursors, resulting in subclonal diversity as the subclones develop 
in parallel.  The large number of mutations and genetic variations result in merely a subset of 
cancerous cells being targeted, while other cells continue to proliferate.  Therefore, a successful 
anticancer treatment must focus on cellular properties that are common to most tumors and are 
intrinsic only to cancer cells, such as tumor-associated acidity.  
 
1.3. Characteristics of cancer cells  
Cancerous tissues are characterized by microenvironmental acidosis (33). The extracellular 
acidity of cancer tissues is associated with hypoxia and heightened cellular metabolic activity (34).  
Tumors have disrupted blood flow due to development of an abnormal vascular network that is 
inefficiently organized, resulting in inadequate oxygen delivery (35).  This leads to poor perfusion 
within the tumor and subsequently low oxygenation.  In turn, insufficient oxygenation heightens 
tumorous cells glycolytic flux.  The high glucose uptake overpowers the ability of the mitochondria 
to produce energy, which then the cytosol resorts to glycolysis even in the presence of normal 
oxygen levels. This is known as aerobic glycolysis or the Warburg effect (34).  Cells will catabolize 
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glucose at an increased rate, and this leads to an increased production of anaerobic metabolites, 
such as protons (H+) and lactate, which are pumped across the plasma membrane into the 
extracellular space (34).  The accumulation of these metabolites in the insufficiently perfused 
regions results in a decrease in the extracellular pH (35).  The release of carbon dioxide from 
cancer cells, which is hydrated to form carbonic acid that dissociates into bicarbonate and H+ and 
is exacerbated by the overexpression of surface carbonic anhydrases (CAIX and CAXII), also 
contribute to the acidic extracellular milieu which supports tumor growth, invasion, aggression, 
and development (36).    
Another characteristic of cancer cells is that their membranes can contain more anionic lipids 
than normal cells at the outer leaflet, leading to an overall negatively charged cell surface. (37, 
38). Normal cells primarily have zwitterionic phosphatidylcholine (PC) and sphingomyelin (SM) 
on the outer leaflet, while phosphatidylethanolamine (PE) and the negatively charged 
phosphatidylserine (PS) are present only in the inner leaflet of healthy cell membranes, resulting 
in an overall net neutral charge from the lipids on the outer leaflet (Figure 1) (39). This asymmetric 
characteristic is maintained by two ATP-dependent translocases (flippase and floppase). Flippase 
actively move the aminophospholipids PS and, to a lesser extent, PE from the outer to the inner 
leaflet, while floppase transports PC and SM from the inner to the outer leaflet. (40).  If the cell is 
damaged and enters apoptosis, the membrane asymmetry is lost due to the inhibition of the 
translocases or a change in the intracellular Ca2+ concentration causing activation of a calcium-
dependent scramblase. Unlike the other two transporters, scramblase is ATP independent and 






Figure 1. Characteristics of cancer cells. Representation of two major differences between 
normal and cancer cells: (i) distribution of phospholipids between the two cell membranes, and 





1.4. Peptides as cancer therapeutics   
As briefly mentioned before, many different membrane active peptides have been developed 
to be used in cancer therapy (15, 21).  These types of peptides are divided into three different 
groups: antimicrobial, cell penetrating, and tumor targeting peptides (Table 1).   
 
1.4.1 Antimicrobial peptides  
The first group consists of peptides that occur naturally or are derived from a protein.  These 
peptides are cytotoxic as they have membrane binding capacity, can form pores or disrupt 
membranes. In addition to being used as a cargo delivery method, these peptides can also be used 
as therapeutic molecules. Antimicrobial peptides fall under this first category. AMPs disrupt the 
integrity of the cellular membrane, typically through formation of a membrane pore. The pore can 
be attained by three different methods: barrel stave, toroidal pore, or as a detergent (22). Many 
AMPs can form alpha helix structures. However, these peptides generally tend to be unstructured 
in solution at physiological pH. In the presence of lipid bilayer, however, they form an amphipathic 
alpha helical structure with their hydrophobic residues aligning one side of the helical axis and the 
hydrophilic residues on the other side (42, 43).   As these peptides generally target lipid 
membranes, drug resistance is less likely to be developed (44).  Cationic AMPs disrupt cell 
membranes and induce apoptosis through electrostatic interactions with anionic components of 
cancer cell membranes (23).  For example, cecropins, isolated from the giant silk moth, have been 
shown to induce cell apoptosis and inhibit cell proliferation in cell culture studies (45). Magainins, 
derived from the African clawed frog also exhibit similar selective anti-cancer behavior. The 
anticancer peptide was toxic to cancer cell, but it did not affect lymphocytes or fibroblast (44). 
While AMP/ACPs have shown great potential, the enzymatic degradation and inactivation of 
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Table 1. Peptide Sequences 
Peptide Type Sequence 
cecropins Antimicrobial KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL2 
magainins Antimicrobial GIGKFLHSAGKFGKAFVGEIMKS 
CADY Cell penetrating Ac-GLWRALWRLLRSLWRLLWRA-Cy 
pep-1 Cell penetrating Ac-KETWWETWWTEWSQPKKKRKV-Cy 
Tat Cell penetrating GRKKRRQRRRPQ 
R8 Cell penetrating RRRRRRRR 
Transportan Cell penetrating GWTLNSAGYLLGKINLKALAALAKKIL 
RGD motif Tumor targeting RGD 
NGR motif Tumor targeting NGR 
TMX-1 synthetic Ac-WNALAAVAAALAAVAAALAAVAAGKSKSKS-NH2 
TMX-3 pH responsive GGWAALAAHAAPALAAALAHAAASRSRSRSR-NH2 
LAH4 pH responsive KKALLALALHHLAHLALHLALALKKA-NH2 
MelP5_Δ4 pH responsive GIGAVLKELADGLPALIDWIEAAQQL 
MelP5_Δ6 pH responsive GIGAVLEELADDLPALIDWIEAAQQL 
pHD* pH responsive GIGEVLHELADDLPDLQEWIHAAQQL 
PSPF* pH responsive WSDLAQALSDLAQALSDLAQALSDLAQA 
aMel pH responsive GIGAVLEVLTTGLPALISWIEEEEQQ-NH2 
aRV pH responsive RIGVLLAELPELFSLFELMGEEV-NH2 
Cyclic pH-Responsive Peptide* pH responsive c[WEWEWEWEWC] 
GALA pH responsive WEAALAEALAEALAEHLAEALAEALEALAA 
pHLIP pH responsive AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG 
ATRAM pH responsive GLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN 
K2-ATRAM pH responsive GKAGKAGLLGLEGLLGLPLGLLEGLWLGLELEGN 
Y-ATRAM pH responsive GYAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN 
*One example of a class of peptides.  







cationic peptides through interaction with negatively charged serum proteins are impediments to 
the clinical use of anticancer peptides. 
 
1.4.2 Cell Penetrating peptides  
Unlike AMPs, the principle mode of action of cell penetrating peptides (CPPs), the second 
group of therapeutic peptides, is to translocate completely across the cellular membrane and 
interact with intracellular targets. Although their exact translocation mechanism is still unknown, 
two main methods have been proposed: (1) an energy independent process and (2) an energy-
dependent endocytic process (46). Many CPPs fall under the latter group including penetratin, Tat, 
and oligoarginines as they are internalized by an endocytotic pathway, while others including 
CADY and pep-1 fall under the former (47, 48). CADY is able to translocate across the plasma 
membrane at low temperatures, indicating an energy-independent process.  Likewise, pep-1 was 
able to translocate beta-galactosidase (β-Gal) across the membrane of lipid vesicles and human 
HeLa cells independently of temperature. In fact, the translocation of β-Gal was due to negative 
transmembrane potential (48, 49). While energy-independent translocation at the plasma 
membrane prevents cargo from being trapped in endosomes, energy-dependent mechanisms may 
result in untimely degradation of the biologically active cargo bound to the peptide during 
endosomal maturation (46). Hence, efficient endosomal escape is essential for energy-dependent 
CPPs.   
CPPs can be classified into two other categories: cationic or amphipathic (15, 50, 51). Similarly 
to AMPs, cationic CPPs are short arginine- and lysine-rich peptides that rely on their cationic 
nature for efficient intracellular accumulation (19).The exemplary Tat peptide is derived from the 
transactivator of transcription (TAT) of HIV and discovered as the first CPP. Mutational analysis 
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of the Tat protein showed that the highly positively charged N-terminus was necessary for the 
entry of the protein into the cell (52, 53).  Studies have shown that the Tat peptide can be used to 
transport a variety of conjugated cargos across the cell membrane, including anticancer drugs (54, 
55). When the anticancer drug Taxol and drug surrogates were conjugated to the cationic CPP 
octaarginine (R8), its solubility, biodistribution, cytotoxicity, and phamacokinetics were enhanced. 
It was also able to overcome multiple drug resistance (56).  Amphipathic CPPs contain both 
hydrophobic and hydrophilic regions. The positively charged and hydrophobic residues are 
distributed evenly throughout the sequence, resulting in the polar residues aligning one face of the 
secondary structure while the nonpolar residues align on the opposite side. Unlike cationic CPPs 
which solely rely on ionic interactions for intracellular accumulation, the main interaction of 
amphipathic CPPs is the binding of its hydrophobic region with the lipid membrane of the cell if 
the peptide has a helical structure in solution (50). If the peptide has a random structure in solution, 
it will still rely on its cationic nature to interact with anionic components on the cell surface (50). 
TP10, the truncated form of the amphipathic transportan, has shown the ability to transport peptide 
nucleic acid into cancer cells (51).  However, an important limitation of most CPPs, like Tat, R8, 
and transportan, is the absence of tumor cell specificity. This necessitates modifications or fusion 
with a tumor-specific ligand for optimal anticancer effectiveness (44). 
 
1.4.3 Tumor Targeting Peptides (TTP) 
The third group of cancer therapeutic peptides are those that are specific for molecular markers 
on the surface of the cancer cell.  Peptides with arginine/glycine/aspartic acid (RGD) or 
asparagine/glycine/arginine (NGR) motifs will bind to integrins overexpressed in tumor 
vasculature.  Once these peptides bind to the receptor, they can be internalized by the cell through 
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endocytosis.  This way they are able to deliver cytotoxic cargo into the cancer cell.  The major 
drawback of the small RGD peptides as therapeutics is their rapid clearance from the circulation 
by the kidneys and the liver (57).  Furthermore, as mentioned previously, the disadvantage of 
focusing on a specific molecular marker is tumor heterogeneity.  
 
1.4.4 Summarized advantages and disadvantages 
Using peptide-based strategies over other drug delivery system has its advantages. Peptides are 
stable in physiological conditions, non-immunogenic, and easy to modify and to conjugate many 
cargoes, such as protein, nanoparticles, or nucleic acids to deliver into cells. While some of these 
peptides mentioned previously were able to inhibit cell proliferation and deliver cargo, many of 
these peptides still lack tumor cell specificity either in vitro or in vivo. However, the ones that do 
have specificity as they contain a motif to target specific proteins are inadequate due to tumor 
heterogeneity.  Moreover, these peptides are rapidly degraded by enzymes when injected into 
animal models.  These are the principle reason why many preclinical and clinical trials based on 
the use of peptides, mostly CPPs, have been conducted or are ongoing, but none of them have been 
approved as a cancer therapeutic by the US Food and Drug Administration (FDA) (54, 58). There 
is a need to find a way for peptides to overcome these limitations. A means to address the 
specificity and tumor heterogeneity is to design peptides to target the extracellular pH of tumor 
cells.   
 
1.5. pH responsive peptides   
Peptides have advantageous properties for application in targeted therapies of acidic diseases. 
Peptides that contain glutamate, aspartate, and histidine are appealing molecules to target acidosis 
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as they can naturally respond to pH alterations close to the physiology range via titration of the 
sidechains. The pKa values of these titratable amino acids (Asp = ~3.5, Glu = ~4.2, His = ~6.6) 
will get shifted in different environments (59). Aspartates and glutamates will have a pKa that is 
typically higher in hydrophobic environments than in solution, while histidine will observe an 
acidic shift (59-63).  In acidic environs, aspartate and glutamate side chains get protonated, which 
increases the overall hydrophobicity of the peptide, which results in an increased affinity for the 
nonpolar region of the cell membrane.  On the other hand, the imidazole sidechain of histidine is 
hydrophobic in its deprotonated state, while it is hydrophilic and positively charged in its 
protonated state. This results in favorable interactions between the peptide and the nonpolar 
regions of the membrane at physiological pH (64). Additionally, therapeutic molecules can be 
attached to the peptides and, thus, be transported across the cellular plasma membrane (Table 1).   
 
1.5.1 TMX 
Several different peptides have been designed to have pH-sensitive properties.  A synthetic 
peptide, TMX-1, was developed and studied by White and colleagues and shown to be able to 
spontaneously insert across lipid bilayers (60, 65).  However, TMX-1 was considered non-
translatable as the peptide strongly aggregated in solution.  In the presence of lipids, it also showed 
conformational heterogeneity of both water-soluble and membrane-bound forms (65).  The issue 
of aggregation was addressed when the peptide was redesigned by including an alanine heptad 
repeat, which results in the formation of alanine coils, and a central proline.  Furthermore, a pair 
of histidines were added to allow pH-dependent changes in peptide topology.  While the 
redesigned peptide, TMX-3, is resistant to aggregation, the peptide was unable to adopt a 
transmembrane (TM) configuration.  It had been proposed that substituting some of the alanines 
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for leucines would result in a hydrophobic state that would result in a peptide that would 
energetically prefer the transmembrane conformation (60).  
 
1.5.2 LAH4 
The synthetic amphipathic LAH4 peptide shows both antimicrobial and cell penetrating 
activity while being designed to be pH sensitive (61). Its higher affinity towards anionic lipids is 
similar to AMPs, and it allows for more specific targeting of membranes with exposed PS (66). 
Similar to CPPs, the polar and nonpolar residues align at opposite sides of the alpha helix. LAH4 
consists mainly of leucines and alanines with lysines at both termini for solubility. Furthermore, 
the addition of lysines allows for electrostatic interactions with DNA and results in high affinity 
for anionic lipids. The pH-sensitivity of the peptide arises from the presence of four histidines (67). 
At neutral pH, the peptide is in its transmembrane state, while the peptide remains on the surface 
of the lipid membrane at pH < 6. With this pH-triggered mechanism, LAH4 is able to deliver DNA 
to cells through endosomal uptake.  As the interior of the endosome acidifies (pH 5.5), the peptide 
that was in its TM state at physiological pH will undergo a conformation change and adopt an in-
plane orientation. This in-plane orientation allows for antimicrobial activity and disrupt the 
endosomal membrane and deliver the DNA to the cytosol (66).  
 
1.5.3 pHD Peptides 
Hristova, Wimley, and colleagues have also attempted to design a pH-sensitive peptide based 
on the analog of the bee venom lytic peptide melittin, MelP5, (68). MelP5 forms pores that, unlike 
melittin itself, are large and can last for hours.  This allows for formation of a channel that 
macromolecules can use to cross the membrane bilayer.  MelP5 was redesigned to control the pore 
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formation of the peptide by pH (MelP5_Δ4 and MelP5_Δ6). Four to six residues have been 
mutated to aspartate or glutamate so that the peptide has pH-responsive properties.  The goal was 
to deliver macromolecules into the cytoplasm through endocytosis.  Endosomal acidification 
should trigger the peptide to form pores and release the macromolecules into the cell.  While the 
pH-sensitive properties were obtained, the mutated analog lost the ability of the parent peptide, 
MelP5, to form macromolecule-sized pores in membranes. With the knowledge they gained with 
the design on MelP5, Hristova, Wimley, and colleagues developed a rational combinatorial peptide 
library. Their goal was to identify sequences that do not permeabilize the membrane at high pH 
and concentration but form macromolecule-sized pores in membranes at pH 5 and low peptide 
concentration. This peptide family is also known as the pH-dependent delivery (pHD) peptides 
(69).   Out of the ten peptides from that library that successfully have the desired properties, the 
ones with five acidic residues were more effective and have a higher apparent pKa than the ones 
with six acidic residues.  The helical spacing on the helix combined with the conserved glutamine 
residue and the preference of glutamate over aspartate suggest that sequence-specific interactions 
affect the  pH-triggered activity of the peptides. 
 
1.5.4 pH-Switchable Pore Formation Peptides 
The pH-switchable pore formation (PSPF) peptides are designed with the premise to form 
pores inside membranes at pH 5.5, which is the pH of the endosomal environment (70).  Degrado 
and colleagues were trying to mimic biological AMPs while overcoming their limitations.  PSPFs 
are disordered and nonspecifically bind to the membrane surface at physiological pH, and they are 
inserted and self-associated to the membrane to form pores at acidic pH. Unlike some AMPs that 
disrupt the membrane by a detergent-like mechanism, the mechanism of PSPF would result in 
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minimal membrane perturbations, and the integrity of the endosome would be maintained.  This 
was shown by the release of ATP and miRNA, but not hemoglobin, from red blood cells, 
suggesting a lack of membrane rupture. Furthermore, their concept for a pore-driven mechanism 
is that lower amounts of peptide are needed compared to a nonselective detergent mechanism that 
necessitates higher peptide density across the entire membrane surface. To enhance their peptide 
design, Degrado and colleagues are considering ways to increase the peptide population of inserted 
state versus the surface-bound state. 
 
1.5.5 AMP Derived pH-Responsive Peptide 
AMPs have previously been used to enhance polyethylenimine (PEI)‐mediated gene 
transfection by increasing endosomal release (71). To improve the transfection efficiency, Zhang 
and colleagues replaced the positively charged residues on melittin and RV-23, a peptide derived 
from Rana draytoni, analogs with glutamates (72).  These new peptides (aMel and aRV) resulted 
in pH‐sensitive lytic activity as the hemolytic activity of both peptides was higher at low pH versus 
physiological pH. The designed peptides interacted with the PEI/DNA complex and were able to 
enhance the PEI‐mediated transfection efficiency as they experienced increased endosomolytic 
activity.  Moreover, they were able to keep low cytotoxicity. 
 
1.5.6 Cyclic pH-Responsive Peptide 
To combat rapid peptide enzymatic degradation, Weerakkody and colleagues have designed 
pH-sensitive negatively charged cyclic peptides (73). Cyclic peptides have shown enhanced 
enzymatic stability compared to linear peptides (74). These novel cyclic peptides demonstrate pH-
sensitive interaction with membranes of liposomes, cultured HeLa cells, and tumors in mice 
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model. As approximately 0.7 kcal/mol of free energy is released at low pH., it is predicted that the 




A well-established synthetic, fusogenic peptide with pH-sensitive membrane-insertion 
properties is the GALA peptide (75, 76).  GALA, named for the residues that make up the majority 
of the peptide (glutamate, alanine, and leucine), goes through a random coil-to-α-helical transition 
when pH is decreased from physiological to acid pH. At acid pH, GALA will insert into lipid 
membranes it as it adopts an amphipathic helical structure due to the protonation of the glutamic 
acid residues. In its helical state, GALA irreversibly aggregates and is inserted into the membrane 
(77, 78).  Furthermore, the peptide is known to self-associate in solution at concentrations higher 
than 16 μM (79). Aggregation is a characteristic of cytolytic behavior in peptides. Indeed, GALA 
at low pH has comparable levels of lytic activity as melittin. However, GALA lacks the positively 
charged amino acids that are proposed to be necessary for the lytic activity of melittin (76).  As 
the peptide was designed with viral fusion protein in mind, GALA does promote membrane fusion 
of small unilamellar vesicles at low pH. Unlike other fusogenic peptides that are only involved in 
vesicle aggregation, such as synexin and polylysine, GALA is involved in both vesicle aggregation 
and the actual fusion steps (80). 
 
1.5.8 pH-Low Insertion Peptides 
Another well-developed pH-responsive membrane peptide is the pH-low insertion peptide 
(pHLIP), which is derived from the C-helix of bacteriorhodopsin (81). In alkaline conditions, the 
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peptide associates with the lipid membrane (peripheral state), while a decrease in pH leads to the 
insertion of pHLIP into the membrane as an alpha helix (transmembrane state; Figure 2) (82, 83).  
While many of the other pH-responsive peptides were designed to behave similarly to AMPs and 
CPPs, pHLIP does not disrupt the integrity of the cell membrane when its inserted unlike GALA 
and the pHD peptides (84, 85).  Furthermore, pHLIP is able to selectively deliver several different 
molecules, such as toxins, nucleic acids, and fluorescence imaging markers, into tumor cells in 
vitro and in vivo (85, 86).  Although cell penetrating peptides and pHLIP both deliver cargo across 
the cell membrane, they differ in the fact that CPPs need to be completely internalized to deliver 
their cargo, while pHLIP does not.  More importantly, pHLIP has been shown to target tumors in 
vivo (87-89). 
The pH-low insertion peptide has several limitations.  Its insertion pK, which is the pH at which 
50% of the peptides are inserted into the membrane, is  pH 5.7 in palmitoyloleoylphosphocholine 
(POPC) liposomes (90).  As the extracellular pH of tumors ranges from 6.4 to 7.0 (91),  pHLIP 
does not localize to the tumor optimally.  Moreover, the insertion pK decreases significantly in 
lipid membranes that include phosphatidylserine (PS) (90, 92).  The insertion pK decreased and 
saturates at approximately 5.3±0.1 at 5% PS (90).  This is rather too acidic for clinical applications 
as the extracellular pH of tumors is more than one whole pH unit higher than 5.3 (33).  For optimal 
cancer cell retention, it would be ideal for the peptide insertion pK to fall within the range of the 
extracellular pH of tumors.  Furthermore, pHLIP has a propensity to aggregate at low 
concentrations (>7 µM). While pHLIP seems successful in laboratory studies, these limitations 
can slow down its transition to clinic trials.    
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Figure 2. Representation of the three different states of pHLIP. Adapted from (93). 
 
  
Soluble Peripheral Transmembrane 
20 
 
1.6. Serum albumin as a carrier in the bloodstream 
As mentioned previously, the major impediment for using peptides as therapeutics is their 
rapid clearance from the circulation due to renal filtration and low metabolic stability. For instance, 
insulin, a proteolytically stable peptide, has a half-life of 4 to 6 minutes once it gets into the 
bloodstream (94). The prevalent approach to avoid this fast clearance is to attach the therapeutic 
molecule to a ligand that binds to serum proteins with long half-lives. As serum albumin is 
responsible for the majority of small molecule binding in plasma, it is the commonly chosen carrier 
molecule in therapeutics (95). Due in part to its size being larger than the renal filtration threshold, 
human serum albumin (HSA) has the high plasma half-life of 19 days (96). It also is the most 
abundant protein in plasma as it accounts for about 50%-60% of plasma proteins.  Insulin detemir, 
insulin degludec, and liraglutide are peptides that are currently used in as therapeutics (97-99). All 
three peptides have been conjugated to a fatty acid chain, such as myristic and palmitic acid, that 
will bind to albumin. All three peptide-albumin complexes resulted in a longer life-time in 
circulation due to reduced filtration by the kidney compared to the nonlipidated peptide version. 
 
1.7. Summary of conducted work   
We designed the acidity-triggered rational membrane (ATRAM) peptide to have pH-
responsive properties so that it can have the duality of being a surface-bound or transmembrane 
peptide (Table 1).  Using biophysical techniques, we have determined that ATRAM is a highly 
soluble peptide that adsorbs onto the lipid membrane surface at physiology and basic pH and will 
fold into the membrane as a transmembrane α-helix at acidic conditions. Its pH-triggered property 
arises from the addition of four glutamates in its sequence. Furthermore, our designed peptide can 
maintain its pH-responsiveness in cultured cancer cells.  
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With additional biophysical experiments and fluorescence microscopy, we gained insight 
to the mechanism of ATRAM’s insertion into liposomes. We determined its membrane topology 
by assessing the cellular uptake of fluorescently labeled ATRAM coupled to PEGylated liposomes. 
The results confirmed that ATRAM inserted unidirectionally with its C-terminus across the plasma 
membrane. Kinetic studies indicated that the peptide undergoes several intermediate steps before 
it is fully inserted into the membrane. In addition, leakage and binding studies gave us insight into 
oligomerization and binding cooperativity.  The peptide exhibits an extended bloodstream 
circulation in mice. We hypothesize that ATRAM uses human serum albumin in the blood to 
circumvent enzymatic degradation as we have shown that the peptide binds to lipid membranes 
after pre-incubation with the protein in biophysical methods.  
Compared to healthy cells, cancerous cells have the negatively charged phospholipid, 
phosphatidylserine, exposed on the outer leaflet of their plasma membranes. With biophysical 
techniques, we determined that the acidity-targeting properties of ATRAM do not change in 
liposomes with increasing concentrations of the negatively charged lipid, but some membrane 
related properties did.  Also, by modifying the sequence of ATRAM at the N-terminus, the 
properties of the peptides were altered, particularly the pK of insertion.  The changes in the 
peptides’ properties are the most significant with the addition of phosphatidylserine.   
My work highlights the potential of ATRAM to be developed as a specific therapeutic 
agent for diseases that lead to acidic tissues, including cancer. Understanding how ATRAM 
interacts with the lipid membrane and is able to avoid immediate degradation and renal clearance 
in vivo can broaden the design and application range of peptides as therapeutics. By rationally fine-
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Several diseases, such as cancer, are characterized by acidification of the extracellular 
environment. Acidosis can be employed as a target to specifically direct therapies to the diseased 
tissue. We have used first principles to design an acidity-triggered rational membrane (ATRAM) 
peptide with high solubility in solution that is able to interact with lipid membranes in a pH-
dependent fashion. Biophysical studies show that the ATRAM peptide binds to the surface of lipid 
membranes at pH 8.0. However, acidification leads to the peptide inserting into the lipid bilayer 
as a transmembrane α-helix. The insertion of ATRAM into membranes occurs at a moderately 
acidic pH (with a pK of 6.5), similar to the extracellular pH found in solid tumors. Studies with 
human cell lines showed a highly efficient pH-dependent membrane targeting, without causing 
toxicity. Here we show that it is possible to rationally design a soluble peptide that selectively 























Targeted therapies hold great promise for the treatment of numerous diseases. This class of 
therapies often relies on the expression of a molecular target in the diseased cell. However, drug 
resistance frequently results from mutation, downregulation, or signaling cross-talk of the 
molecular target (101). The successful targeted therapies of the future will benefit by being 
directed instead at a prevalent feature of the disease. Several pathological states, such as cancer 
(102), ischemia, and inflammation, have a significantly disrupted pH balance resulting in acidosis. 
In the case of cancer, alterations in the metabolism and physiology of solid tumors cause 
extracellular acidosis (34, 103). Strikingly, it has been recently shown that acidosis favors tumor 
aggressiveness. In particular, acidity enhances metastasis (104) and local invasion (35) and plays 
an immunosuppressive role (105). Therefore, technologies that target therapeutic cargos to acidic 
tissues might be of general use for fighting acidic diseases such as cancer. Furthermore, as a 
consequence of the competitive advantage acidosis confers to cancer cells, therapies targeting 
acidosis might be less susceptible to resistance.  
Peptides are attractive molecules for the delivery of cargo to acidic diseased tissues. Peptides 
show high efficacy, selectivity, and safety (106) and are also naturally endowed to respond to 
acidification, by means of the titration of the acidic residues aspartate and glutamate. Here, we 
report the rational design of an acidity-triggered rational membrane (ATRAM) peptide, which 
responds to acidification by inserting into the membrane of tumor cells. 
 
2.3. Experimental Procedures 
 
Liposome Preparation. Stocks of POPC (1-palmitoyl-2- oleoyl-sn-glycero-3-phosphocholine) 
(Avanti Polar Lipids, Inc.) were prepared in chloroform. Appropriate aliquots of lipids were dried 
first with argon gas and then under a vacuum overnight. The dried lipid films were rehydrated 
26 
 
using 10 mM NaPi buffer (pH 8.0). Large unilamellar vesicles (LUVs) were prepared with a Mini-
Extruder (Avanti Polar Lipids, Inc.) through a 100 nm pore size membrane (Whatman).  
Peptide Preparation and Conjugation. Peptides were prepared by FMOC solid phase synthesis 
and purified by reverse phase high-performance liquid chromatography to >95% purity. For 
biophysical experiments, the ATRAM peptide was labeled at the N-terminus with NBD 
(nitrobenzoxadiazole) using NBD-X succimidyl ester or rhodamine (5,6-carboxytetramethyl-
rhodamine, succinimidyl ester, Anaspec). For microscopy, ATRAM and pHLIP were labeled at 
the N-terminus with BODIPY FL-X, which contains a seven-atom spacer between the dye and the 
conjugation point. Free dyes were removed by gel filtration through a PD-10 column, and matrix-
assisted laser desorption ionization time of flight was employed to determine that a single dye 
molecule was bound per peptide molecule. The expected and observed molecular mass (M + H+) 
values were 3623.1 and 3624.0, respectively.  
NBD Lipid Binding Assay. The assay was performed as described elsewhere.9 Briefly, 
lyophilized samples of ATRAMNBD were rehydrated in 10 mM NaPi (pH 8) at a final 
concentration of 1 μM and incubated with increasing concentrations of POPC LUVs. Emission 
spectra were recorded on a Photon Technology International Quanta Master fluorometer. The 
appropriate lipid background was subtracted in all cases. Data were analyzed by following the 
fluorescence intensity change at 540 nm. Data were fitted with OriginLab using eq 1: 
Fo +  ∆F ×
Kp × x
55.3+Kp × x
  (1), 
where Fo is the initial fluorescence intensity, Fmax is the maximal fluorescence intensity, x is the 
lipid concentration, and 55.3 is the molar concentration of water. Equation 1 was used to determine 
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the partition coefficient, Kp, defined as the ratio of concentrations of a compound in a mixture of 
two phases. 
Intrinsic Fluorescence Spectroscopy. For the pH titration experiments, 1 μM ATRAM was 
incubated for at least 1 h with POPC LUVs to reach a 1:200 molar ratio. The pH of the samples 
was changed accordingly with 100 mM buffers (sodium acetate, MES, or HEPES). Tryptophan 
fluorescence emission spectra were recorded at an excitation wavelength of 280 nm. 
Measurements were performed on a Photon Technology International Quanta Master fluorometer. 
The appropriate lipid background was subtracted. The data were analyzed by monitoring the 
spectral maxima, which were then fitted to determine the pK, using eq 2:  
𝐹𝐹𝑎𝑎+𝐹𝐹𝑏𝑏 ×10𝑚𝑚(𝑝𝑝𝑝𝑝−𝑝𝑝𝑝𝑝)
1+10𝑚𝑚(𝑝𝑝𝑝𝑝−𝑝𝑝𝑝𝑝)
  (2), 
where Fa is the acidic baseline, Fb is the basic baseline, m is the slope of the transition, and pK is 
the midpoint of the curve.  
Circular Dichroism. Measurements were performed on a Jasco J-815 spectropolarimeter at 25 
°C. Peptide was incubated with lipid in 10 mM NaPi (pH 8.0) or 10 mM sodium acetate (pH 4.1). 
Samples were prepared as described above. The lipid:peptide ratio was 100:1 with a final peptide 
concentration of 5 μM. The appropriate lipid backgrounds were subtracted.  
Oriented Circular Dichroism. OCD was performed as described elsewhere (90). Briefly, the 
Langmuir−Blodgett method was used to form a monolayer on a demountable quartz cuvette with 
a KSV NIMA trough. A peptide/lipid solution (1:50 molar ratio) at pH 4 or 8 was incubated with 
the monolayer under 100% humidity to complete vesicle fusion to obtain supported bilayers. The 
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OCD spectrum was measured on a Jasco J-815 spectropolarimeter, and appropriate backgrounds 
were subtracted.  
Calcein Leakage Assay. A dried POPC lipid film was rehydrated with 50 mM calcein in 10 mM 
HEPES and 50 mM EDTA (pH 8). Large unilamellar vesicles were prepared as described above. 
Free calcein was removed by gel filtration through a PD-10 column. Peptide was added to the 
calcein/ LUV suspensions at different concentrations to achieve final peptide:lipid molar ratios of 
0.0025−0.5%. After incubation at room temperature for 30 min, calcein leakage was tracked by 
measuring fluorescence using a Synergy 2 microplate reader (BioTek) at an excitation wavelength 
of 485 nm and an emission wavelength of 528 nm. Complete calcein release was reached by adding 
20% Triton X-100.  
FRET Oligomerization Assay. Lyophilized samples of ATRAM, ATRAM-NBD (donor), and 
ATRAM-Rho (acceptor) were rehydrated in 10 mM NaPi buffer (pH 8). The donor was held at 
0.1 μM, and the acceptor was used in a range of concentrations from 0 to 0.5 μM. Unlabeled 
peptide was added to keep the final peptide concentration constant at 2 μM. To minimize 
scattering, polarizers were employed: excitation polarizers set to 90° and emission polarizers set 
to 0° (107, 108). Lipid blanks were subtracted in all cases. The final lipid:peptide ratio was 200:1.  
Vesicle Fusion Assay. FRET was used to determine the amount of vesicle fusion induced by 
ATRAM. PE-Rho and PENBD were from Avanti Polar Lipids. Vesicles containing 99 mol % 
POPC, 0.5 mol % PE-NBD (donor), and 0.5% PE-Rho (acceptor) were prepared like POPC 
vesicles. The final ATRAM concentration was 1.9 μM. Unlabeled POPC vesicles were added to 
vesicles containing labeled lipids in the presence of ATRAM. POPC vesicles containing labeled 
lipids were measured separately to determine the maximal amount of energy transfer. Triton X-
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100 (final concentration of 0.7%) was added to samples containing POPC vesicles with labeled 
lipids to inhibit the FRET signal to determine the smallest amount of energy transfer. Appropriate 
lipid blanks were subtracted from each sample to correct for the effect of light scattering caused 
by lipids. POPC vesicles containing 0.5 mol % PE-Rho in the absence and presence of Triton X-
100 were used to determine the correction factor to account for the disturbance in the emission 
spectra caused by the addition of Triton X-100. The percent fusion was calculated using eq 3: 
(sample−control)
(𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇−𝑐𝑐𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑐𝑐)
 × 100 (3), 
where Sample contains ATRAM, labeled vesicles, and unlabeled vesicles; Control is identical but 
without ATRAM; and Triton is POPC containing labeled lipids after the addition of Triton X-100. 
All intensity values were measured at 594 nm. 
Cell Binding Assays: Plate Reader and Confocal Microscopy.  A375 and H358 cells (ATCC) 
were washed twice with phosphate-buffered saline supplemented with 1 mM MgCl2 and 100 μM 
CaCl2 (PBS++) and incubated with 2 μM peptide (ATRAM-BODIPY or pHLIP-BODIPY) for 5 
min, followed by an incubation of 90 s with PBS++ containing 10 mM dextrose (Sigma-Aldrich) 
at different pHs (5, 6, and 7). Cells were then washed once in the same buffer and subsequently 
fixed with 4% paraformaldehyde for 30 min. Plate reader binding assays were performed using 
cells cultured in a 96 black collagen-coated plate (Corning), and the fluorescence intensity was 
detected at 488 nm in a plate reader (Synergy 2, Biotek). The quantification analysis is a result of 
three independent experiments performed in triplicate. Cell imaging was performed at room 
temperature using an inverted Olympus Ix83 microscope with a confocal laser scanning 
VTHAWK system equipped with a 60 × 1.35NA objective from Visitech International, running 
metamorph, and a Hamamatsu EM-CCD camera (model C9100-13). Contrast and brightness 
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settings were chosen so that all pixels were in the linear range. Images from different channels 
were overlaid using ImageJ.  
Cell Proliferation Assay (MTS). Cell viability was measured using the CellTiter 96 Aqueous One 
Solution. Briefly, cells were seeded (104 cells/well) 2 days prior the experiments on a 96-well 
plate, exposed to vehicle (CT) or ATRAM at different concentrations (0.5, 1, and 2 μM), and 
incubated for 24 h. The results are representative of three independent experiments, performed in 
quadruplicate. The inhibition of cell proliferation was expressed as the percentage of vehicle 
control. 
2.4. Results 
The potential of peptides for targeting acidosis is exemplified by the pH-low insertion peptide 
(pHLIP). The pHLIP, developed in the laboratories of Engelman, Reshetnyak, and Andreev, is a 
soluble peptide that binds to membranes in a mostly unstructured conformation at neutral pH. 
Upon acidification, the pHLIP undergoes a conformational change, forming a transmembrane 
(TM) α-helix as it spans the membrane (81, 109, 110). Several residues important for pHLIP 
properties, such as the acidic groups responsible for the pH dependency, and a central proline 
residue that increases solubility (111), were included in the sequence of the ATRAM peptide 
(Figure 3A). Glutamates were chosen over aspartates, because they have higher pKa values, more 
appropriate for the targeting of acidic diseased tissues. For the rest of the ATRAM sequence, 
residues were selected to yield an overall hydrophobicity similar to that of pHLIP (112) by 
balancing the more hydrophobic leucine with the less hydrophobic alanine and glycine (Gly). Gly 
was preferred over alanine because, interestingly, the conformational propensity of Gly is strongly 
dependent on the environment. Hence, while in solution Gly destabilizes the secondary structure 
found in aggregates, in membranes Gly favors the formation of helices (113, 114). Hence, we 
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believe that Gly minimizes aggregation in solution without disrupting α-helix formation in 
membranes. Finally, a single tryptophan residue was introduced into the ATRAM peptide to 
perform intrinsic fluorescence evaluation of the properties of the peptide. 
We found that ATRAM readily dissolved in aqueous buffer (see details below), allowing us to 
evaluate the interaction with lipids. We first studied the binding of the ATRAM peptide to 
synthetic vesicles. As a lipid of choice, we selected POPC, because its phosphatidylcholine 
headgroup is the most abundant in the eukaryotic plasma membrane (115, 116), while also 
containing saturated and unsaturated fatty acids. To accurately measure the binding of ATRAM to 
POPC LUVs, we labeled the peptide with an environmentally sensitive fluorescent probe, NBD 
(90). We observed that incubation with POPC at pH 8.0 caused a large increase in the fluorescence 
of the NBD conjugated to ATRAM (Figure 3B, blue symbols), as well as a blue-shift in the spectral 
maximum (Figure 3B, inset). Both spectral changes are characteristic of dehydration of the NBD 
group (117-119), suggesting that ATRAM binds to lipid membranes. We next studied whether the 
interaction of ATRAM with membranes was pH-responsive, as required for the targeting of 
diseased cells in acidic environments. For this purpose, we monitored the intrinsic fluorescence of 
the single tryptophan residue (Figure 3A, underlined). A pH titration experiment was performed 
for samples of ATRAM incubated with POPC. Upon acidification, we observed a blue-shift in the 
emission spectrum from ∼340 to ∼330 nm and a large increase in fluorescence (Figure 3C). From 
the obtained spectral maximum curve, we determined the membrane insertion pK, defined as the 
midpoint of the sigmoid, with a value of 6.51 ± 0.09. The blue-shift of the intrinsic fluorescence 
of ATRAM indicated that at acidic pH values the tryptophan in the peptide was more deeply buried 
in the membrane than at neutral pH, suggesting a tighter interaction. To evaluate how membrane 
affinity could depend on pH, we repeated the NBD lipid binding experiments at pH 6.0 (Figure 
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3B, red symbols). We observed that ATRAM bound more readily to POPC at pH 6.0 than at pH 
8.0. We analyzed the binding isotherms to determine the partition coefficient, Kp, with values of 
(5.5 ± 2.5) × 105 at pH 8.0 and (16.5 ± 2.5) × 105 at pH 6.0, demonstrating that ATRAM binds to 
membranes with higher affinity under acidic conditions. 
To study the conformation of ATRAM in the membrane, we employed circular dichroism (CD) 
spectroscopy (Figure 3D). At pH 8 (blue line), the CD spectrum showed a minimum of 204 nm 
and a small shoulder at 222 nm. These spectral features are typically observed for partially 
disordered peptides with some helical content (120). Interestingly, at acidic pH (red line), the 
helical content increased, as shown by the large decrease in the magnitude of the signal at 222 nm, 
the shift of the minimum from 204 to 208 nm, and the large increase in ellipticity at 195 nm. We 
performed a rough quantification of the helical content at both pH values. By considering for 100% 
α-helix a [Θ] of −36000 deg cm2 dmol−1 residue−1 (121), we estimated that the helical content 
increased from ∼12% at pH 8 to ∼37% at pH 4. However, the membrane alignment of the helical 
region of ATRAM was not known. To gain information about the helical orientation with respect 
to the plane of the bilayer, we prepared supported bilayers and performed oriented CD (OCD) 
experiments (122, 123). When α-helices span the membrane, the OCD spectrum characteristically 
displays a broad minimum at ∼220−225 nm and a shoulder with positive ellipticity at 190−195 
nm. These characteristics were observed at acidic pH (Figure 3D, inset), indicating that ATRAM 
adopts a TM orientation at low pH. On the other hand, the OCD spectrum of an α-helix lying 
parallel to the plane of the membrane shows a much more intense negative signal and more clearly 
resolved minima at ∼205 and ∼222 nm, which are similar to our data at pH 8. The OCD data thus 
indicate that ATRAM lies parallel to the membrane plane at neutral pH, but it responds to 











Figure 3. Biophysical characterization of the ATRAM peptide. (A) Sequence of ATRAM. The 
acidic moieties, glutamic acid and free C-terminus, are shown in bold; proline is shown in italics, 
and the single tryptophan introduced for intrinsic fluorescence experiments is underlined. The 
sequence of pHLIP is shown for comparison. (B) POPC binding assay of ATRAM-NBD (1 μM) 
at pH 8.0 (blue symbols) and pH 6.0 (red symbols). The fluorescence intensities were normalized 
to the maximal value. Curves were fitted to eq 1 (black lines). The inset shows the NBD 
fluorescence spectra at 10 and 400 μM POPC (solid and dashed lines, respectively) at pH 8. (C) 
Representative pH titration curve obtained by monitoring the tryptophan fluorescence spectral 
maximum of ATRAM in POPC (n = 4). The line is the fitting to eq 2, to determine the pK and the 
slope of the titration. The slope obtained for ATRAM (1.6 ± 0.4) was similar to the value for the 
pHLIP in the same lipid (1.2 ± 0.3) (92). The inset shows the tryptophan fluorescence spectra of 
ATRAM in POPC LUVs at pH 4.3 (red line) and pH 7.7 (blue line). (D) Circular dichroism spectra 
of ATRAM in POPC at different pH values. Data shown for the ATRAM peptide with POPC 
vesicles at pH 7.9 and 4.1 (blue and red lines, respectively). The inset shows the OCD spectra in 








Toxicity to Healthy Cells Poses a Significant Concern in the Design of Membrane Active 
Peptides. Numerous examples of peptides that disrupt membranes by formation of pores or 
membrane solubilization or fusion exist (55, 77, 124-126). To rule out the possibility that ATRAM 
might disrupt the integrity of cell membranes, we performed different assays on lipid vesicles and 
cells. We studied first whether ATRAM induced vesicle fusion or hemifusion by performing a 
FRET assay with two different fluorescently labeled lipids. Figure 4A shows that ATRAM induced 
no statistically significant fusion or hemifusion of POPC LUVs, neither at pH 8.0 nor at pH 4.0. 
We also performed an assay to study vesicle leakage of encapsulated calcein. A previous report 
showed that pHLIP caused only minor calcein release, in agreement with data indicating that 
membrane integrity is not significantly disrupted by pHLIP (84). We performed a similar assay 
comparing pHLIP and ATRAM (Figure 4B). We observed that the signal was similar for both 
peptides at most peptide:lipid ratios, and only slightly higher for ATRAM at the highest 
concentration. Intrigued by the leakage results in synthetic vesicles, we performed an assay to 
study whether ATRAM disrupted the membrane of cells. We performed a cell viability assay in 
two different cell lines (Figure 4C) that shows that ATRAM does not cause cell toxicity. This 
result indicates that ATRAM did not disrupt cellular membranes at any of the concentrations 
assayed. 
To study whether the ATRAM peptide was capable of self-assembly, we performed 
oligomerization assays in solution and in the membrane-inserted state at pH 4. Protein 
oligomerization is typically associated with a folded state, because protein− protein interfaces tend 
to adopt a well-defined conformation. We first employed CD to determine the structure adopted 
by the ATRAM peptide in solution. The CD spectrum at 5 μM displays a minimum at ∼200 nm, 
indicating that the peptide is largely unstructured. However, a small shoulder at 222 nm suggests  
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Figure 4. Membrane interaction of the ATRAM peptide. (A) FRET vesicle fusion assay. The 
effect of ATRAM on vesicle fusion/hemifusion was determined at pH 4.0 (TM state, left) and pH 
8.0 (interfacial state pH, right). The curves show data from vesicles in the absence of peptide 
(dashed red line), in the presence of peptide (blue line), and membrane disruption by Triton X-100 
(green line). (B) Comparison of the effect of ATRAM and pHLIP on membrane leakage. The 
fluorescence intensity of calcein encapsulated in POPC vesicles was monitored after the addition 
of peptide (0.0025−0.5 mol %) in 10 mM NaPi (pH 8.0): (○) ATRAM and (●) pHLIP (n = 3). (C) 
MTS cell viability assay performed in the presence of ATRAM for two different human cell lines: 
A358 (black) and H358 (gray). Data show the cell viability at increasing ATRAM concentrations 
compared to that of nontreated control cells (CT). Results are the means of three independent 
experiments. No statistically significant cell toxicity was observed at any of the ATRAM 
concentrations. (D) Solubility studies of ATRAM in a 10 mM NaPi solution (pH 7.9) at increasing 
concentrations. CD spectra are shown for 5 and 200 μM peptide (solid and dashed lines, 









minor helical structure (Figure 4D). Increasing the peptide concentration to 200 μM caused only 
small CD changes, which suggest a minor increase in helicity from ∼5 to ∼10%.25 We obtained 
further insights by monitoring the intrinsic fluorescence of ATRAM at increasing concentrations 
(Figure 4D, inset). At all concentrations, the sole tryptophan in the peptide was highly solvated, as 
indicated by the spectral maximum between 350 and 352 nm. Nonetheless, a small, seemingly 
nonlinear shift was observed, compatible with the presence of some concentration-dependent 
peptide self-association in solution. However, because the peptide at 200 μM is largely unfolded,  
and the tryptophan is highly hydrated, we favor the possibility that the monomer is the main species 
present even at high concentrations. Finally, we performed a FRET experiment to characterize 
whether ATRAM self-associated in the TM form (Figure 5). We observed FRET efficiency values 
higher than those expected for a monomer (○), suggesting that ATRAM is in an oligomeric state. 
Figure 5 shows data obtained under similar conditions for helix α5 of Cry1Ac (△), postulated to 
form a transmembrane tetramer (127, 128).  The FRET of ATRAM was significantly lower, 
suggesting that the ATRAM peptide assembles into a small oligomeric species, a dimer or a trimer. 
Our data showed that ATRAM interacted in a pH-dependent fashion with synthetic vesicles. 
However, it was critical to establish whether the desirable properties of the peptide were 
maintained in cells. The ability of ATRAM to bind to cultured cells was studied first by 
fluorescence microscopy for two different human cancer cell lines, A375 (malignant melanoma) 
and H358 (bronchioalveolar carcinoma) (Figure 6A). To explore whether ATRAM showed 
potential for targeting acidosis, experiments at decreasing pH values were performed in parallel 
with the well-established pHLIP (86, 109, 110, 129). We labeled both peptides with a fluorescent 
dye, BODIPY FL-X, to monitor their cellular distribution. After a brief incubation with the 








Figure 5. Self-assembly of the ATRAM peptide. The oligomerization of the TM state of 
ATRAM was studied using FRET. Panel A shows the fluorescence spectra. Increasing amounts of 
ATRAM-Rho (acceptor) were added to the samples, and the intensity of the FRET signal increased 
through quenching of ATRAM-NBD (donor), which was kept at a constant concentration (n = 3). 
Panel B shows the calculated FRET efficiency values for ATRAM (●). The line shows the 
theoretical FRET efficiency values expected for random encounters of a TM monomeric peptide 
(○) (82, 130). To guide the discussion, we show FRET data for oligomeric helix α5 of Cry1Ac of 












Figure 6. pH-dependent interaction of ATRAM with cells. (A) Confocal images of ATRAM-
BODIPY and pHLIP-BODIPY in two cell lines: A375 (top row) and H358 (bottom row). Images 
compare the pH-dependent targeting of cells by ATAM and pHLIP. The gain employed was 
identical in all panels and selected to avoid saturation of the ATRAM pH 5 samples. Typical results 
from one of three experiments are presented. The bar is 20 μm. (B) Plate reader quantification at 
pH 5.0 (black), pH 6.0 (gray), and pH 7.0 (white). Data were normalized to the maximal 
fluorescence detected in each experiment. Results are means of three independent experiments, 
and the error bars show the standard deviation. Student’s t test: NS, nonsignificant; *p < 0.05; and 






















evaluated. Interestingly, ATRAM was able to bind to cells in a pH-dependent fashion, with 
stronger cell interaction at acidic pH values. To quantify the association with cells, the total 
fluorescence signal for the bound peptides was measured in a plate reader assay. Figure 6B depicts 
the quantification of the pH-dependent interaction with the two cell lines. The results indicated 
that the overall level of binding of ATRAM to both cell lines was higher than for pHLIP. 
Furthermore, it was evident that ATRAM targeted more efficiently cells in acidic environments. 
Taken together, our results indicate that ATRAM is capable of targeting cells, and this ability is 
significantly greater under acidosis, without causing toxicity. 
 
2.5. Discussion 
We are currently in the midst of a golden era in the protein design field. A substantial number 
of exciting successes have been recently achieved to engineer protein functions and structures 
employing different computational tools (131, 132). For example, the Rosetta method allows the 
de novo design of certain small soluble and membrane proteins with different functions (133, 134). 
In the membrane protein field, DeGrado and coworkers have been able to computationally design 
transmembrane peptides that inhibit integrins (135) as well as to create membrane helical bundles 
of diverse functionalities (136, 137). However, synthetic biological elements can be created 
without computationally intensive methodologies. Protein design can also be undertaken by 
employing first principles and guided by experimental data. A salient example is the maquette 
method of the Dutton laboratory, which allows engineering of an astounding variety of 
oxidoreductase functionalities into four helix bundles (138). Upon application to membrane 
proteins, it is also worth mentioning the pioneering work in which synthetic peptides were 
assembled into membranes forming an ion channel (139). 
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Here we wanted to design de novo a water-soluble peptide whose interaction with lipid 
membranes was controlled by pH. Despite its small size, designing this kind of molecule is 
challenging, because the peptide is required to be stable in environments of very different 
hydrophobicities (aqueous solution and the membrane) (140). Furthermore, acidification should 
efficiently trigger insertion into the membrane. While the pHLIP has been successfully applied for 
imaging (141) and drug delivery across membranes (142, 143) for various solid tumors, several 
features potentially restrict its use. These include modest targeting of mildly acidic tumors (141) 
and a relatively strong tendency to aggregate (82). To overcome these limitations, sequence 
refinement of pHLIP is desirable (144). However, progress has been hindered as a result of the 
lack of solubility commonly found in single mutants of pHLIP (145). The peptide described herein 
was designed to fill this need. Learning from pHLIP, we designed the ATRAM peptide with a 
sequence that was only 23.5% identical to the sequence of pHLIP. 
The ATRAM peptide is highly soluble in pH 8 buffer, where it remains in a largely 
unstructured conformation. As projected, it is capable of binding to lipid vesicles at neutral pH, 
and under acidic conditions, it forms an α-helix that aligns perpendicular to the membrane plane. 
We hypothesize that a feature important for understanding the mechanism of ATRAM is the 
increase in helical content associated with the coupled membrane insertion and folding (Figure 
3D). In the surface bound, preinserted state, few peptide backbone hydrogen bonds are formed. 
Hydrogen bonds are more energetically favored in the low-dielectric membrane core (146). 
Therefore, formation of backbone hydrogen bonds integral to a TM helix will drive membrane 
insertion of ATRAM. The OCD data indicate that ATRAM forms a TM α-helix at acidic pH. The 
magnitude of the CD signal suggests that the TM state of ATRAM includes long disordered 
stretches. It is likely that those correspond to the two ends of the sequence, while the central region 
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spans the membrane. Interestingly, quantification of the CD α-helical content would suggest that 
the TM region of ATRAM might be shorter than the 20 residues typically found in TM domains 
(146, 147). Nonetheless, quantification of secondary structure percentages by CD is often 
associated with significant errors (148). However, we are confident that the ellipticity at 222 nm 
of ATRAM is compatible with a transmembrane span, because a very similar CD spectrum is 
observed under conditions where pHLIP forms a TM domain (82, 144). 
We Are Currently Evaluating the Directionality of the Insertion of ATRAM into 
Membranes. Understanding which end of the peptide leads the membrane insertion is a 
prerequisite for employing ATRAM for therapeutic purposes. We hypothesize the ATRAM 
peptide will behave like the pHLIP, which inserts unidirectionally and fully translocates the C-
terminal end across the membrane. This allows the pHLIP to deliver cargoes of different sizes and 
polarities across the membrane (110). In case it is determined that the inserting end of the ATRAM 
peptide does not fully traverse the membrane, peptide design will be optimized to elongate the 
inserting end. A crucial feature of ATRAM is the use of multiple glutamic acid residues (149, 
150), as the negative charges provide pH-sensing capability. Conveniently for our purposes, the 
pKa values of acidic groups in hydrophobic environments are typically higher than when they are 
hydrated (150, 151). Hence, while a Glu side chain has a pKa of ∼4.0 in solution, values as high 
as 8.8 have been reported for Glu in different environments (152). It is then not surprising that the 
pK of ATRAM resulting from the titration of Glu was 6.5, while it is 6.0 for pHLIP. In fact, the 
half-unit pK difference between ATRAM and pHLIP corresponds to the pKa difference between 
Glu and Asp in solution. The side chain of Glu also increases the water solubility of the ATRAM 
peptide, as a result of its low hydrophobicity. 
The design of membrane peptides is often complicated by their disruption of lipid bilayers. For  
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example, the GALA peptide, also rich in glutamic acids, has been shown to cause 
bilayersolubilization and membrane fusion (77, 80). Figure 4A shows that ATRAM does not cause 
fusion or hemifusion of POPC vesicles. We also performed leakage experiments to evaluate the 
integrity of the membrane, using pHLIP as a control for a nondisruptive peptide. Our data show 
that the leakage observed for pHLIP, while still small, was higher than the value previously 
reported (84). We attribute these differences to the high sensitivity of our calcein assay, where the 
leakage value reported might be artifactually increased. For instance, in our hands, careful pipet 
sample mixing resulted in calcein leakage, maybe as a result of physically stressing the vesicles. 
Nevertheless, we observed similar calcein leakage for pHLIP and ATRAM except at the higher 
peptide concentration, 0.7 μM. If ATRAM did in fact significantly disrupt the integrity of 
membranes, we would expect it also to cause cell toxicity. However, viability studies in two 
different cell lines showed that ATRAM caused no toxicity, even at a concentration (2 μM) higher 
than that employed for the leakage assay, showing that the peptide is not toxic to cells in culture. 
FRET experiments also showed that ATRAM forms a TM oligomer in the membrane under acidic 
conditions (Figure 5B). The FRET data suggest the presence of dimers or trimers. We suggest that 
ATRAM might form a dimer, because it contains GxxxG domains, which have been identified to 
induce dimerization in numerous transmembrane domains (153, 154). 
Two interesting works that describe different efforts to design peptides with pH-dependent 
membrane insertion have recently been published. The DeGrado group computationally designed 
a series of peptides and evaluated their ability to form pores in the membrane upon acidification 
(70). Oligomeric assembly was achieved both in solution and in the presence of membranes, where 
the peripheral state was postulated to exchange into a transmembrane pore. The groups of Hristova 
and Wimley employed a different approach, decorating the lytic peptide melittin with different 
43 
 
acidic residues (68). While macromolecular release across the membrane was not achieved in this 
case, interestingly, the resulting peptides were able to form an α-helix in POPC vesicles in a pH-
dependent fashion. However, the orientation of the helix was not determined, and the pK values 
were highly acidic, between 4.6 and 5.0. 
Malignant solid tumors typically have an extracellular environment with a pH value of 6.5−6.9 
(155), significantly more acidic than healthy tissues, where the extracellular pH is 7.2−7.4.6 
Interestingly, the membrane insertion pK of the ATRAM peptide is 6.5, suggesting that it might 
be effective in targeting malignant solid tumors. Our data show that the targeting of cells by 
ATRAM is very efficient, and importantly, the level of targeting is significantly higher under 
acidic conditions (Figure 4). Interestingly, for the A375 melanoma cells, strong targeting was 
achieved at pH 5.0 and 6.0, suggesting that high acidity is not required for efficient cell targeting. 
It has been previously reported that the membrane insertion pK of pHLIP differs between cells 
with differing lipid compositions (156). A similar behavior might account for the observed 
requirement of higher acidity for maximal ATRAM insertion in H358 cells (Figure 6B). 
Interestingly, for both cell lines, we observed a higher level of targeting by ATRAM than by 
pHLIP. This might be partially explained by the slightly higher lipid affinity of ATRAM. Hence, 
while the POPC partition coefficient, Kp, of ATRAM at pH 8 was (5.5 ± 2.5) × 105, the Kp of 
pHLIP obtained under identical conditions was (2.1 ± 0.4) × 105 (90). The targeting differences 
observed between the two cell lines might also be associated with the distinct cellular distribution 
for ATRAM. In H358 cells, ATRAM localizes primarily to the plasma membrane, while in A375 
cells, it is also heterogeneously distributed across the cytoplasm, probably at endocytic vesicles. 
We observed a similar trend for pHLIP, in agreement with a previous suggestion that pHLIP might  
leave the plasma membrane because of membrane recycling and/or endocytosis (143). 
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Here we show that ATRAM is soluble at high concentrations, at least up to 200 μM. This 
contrasts with the case for pHLIP, for which peptide aggregation is observed above 7 μM (82). 
When membranes are available, ATRAM binds to the bilayer surface, adopting a partially helical 
structure that lies parallel to the membrane plane. Finally, acidity drives ATRAM to insert, forming 
a transmembrane helix, which increases its affinity for membranes. The POPC insertion pK of 
ATRAM was 6.5, suggesting that ATRAM might be able to target the more frequent mildly acidic 
diseased tissues. The observed lack of cellular toxicity and the efficient targeting of cells in an 
acidity-dependent fashion suggest that ATRAM might be a promising new tool for targeted 
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pH-responsive peptides are promising therapeutic molecules that can specifically target the plasma 
membrane in the acidified extracellular medium that bathes cells in tumors. We designed the 
acidity-triggered rational membrane (ATRAM) peptide to have a pH-responsive membrane 
interaction. At physiological pH, ATRAM binds to the membrane surface in a largely unstructured 
conformation, while in acidic conditions it inserts into lipid bilayers forming a transmembrane 
helix. However, the molecular mechanism ATRAM uses to target and insert into tumor cells 
remains poorly understood. Here, we determined that ATRAM inserts into cancer cells with a 
preferential membrane orientation, where the C-terminus of the peptide traverses the plasma 
membrane and explores the cytoplasm. Using biophysical techniques, we determined that the 
membrane interaction of ATRAM is contingent on the concentration of the peptide. Kinetic studies 
showed that membrane insertion occurs in at least three steps, where only the first step was affected 
by the membrane density of ATRAM. These observations, combined with membrane binding and 
leakage data, indicate that the interaction of ATRAM with lipid membranes is dependent on its 
oligomerization state. SPECT/CT imaging in mice revealed that ATRAM accumulates in the blood 
pool, where it has a prolonged circulation time (> 4 hours). Since fast peptide clearance and 
degradation in circulation are major problems for clinical development, we studied the mechanism 
ATRAM uses to remain in the blood stream.  Using binding and transfer assays, we determined 
that ATRAM binds reversibly to human serum albumin. We propose that ATRAM uses albumin 
as a carrier in the blood stream to evade clearance and proteolysis before interacting with the 
plasma membrane of cancer cells. We also show that ATRAM is able to be deliver liposomes to 
cells in a pH dependent way. Our data highlight the potential of ATRAM as a specific therapeutic 





Cancer nanotechnology and nano-architectonics are being intensively studied to be used as 
cancer diagnosis and treatment (157, 158).  It has been shown that the accumulation of 
nanoparticles in tumors have been improved due to the enhanced permeability and retention (EPR) 
effect. However, the total accumulation of nanoparticles to tumors often remains low (159). To 
overcome this problem, peptides have been utilized to actively target the nanoparticles to tumor 
sites (160-162). Not only do peptides improve the tumor targeting of nanoparticles, they also 
enhance stability (161, 163).  Targeting peptides can improve the specificity and efficiency of 
delivery of nanoparticles and cancer drugs, as they can selectively bind to specific targets, such as 
cell surface receptors and ion channels (106, 164). Especially interesting are peptides able to 
overcome the hydrophobic core of the plasma membrane, which is a major obstacle for 
intracellular delivery of drugs (165, 166).  The ability to fine-tune peptides according to amino 
acid properties allows for targeting of distinct markers and environmental triggers. For instance, 
de novo antimicrobial peptides (AMPs) are designed to be similar to natural AMPs. AMPs have a 
high overall positive charge allowing them to interact with the negatively charged lipid headgroups 
present in membranes of bacteria and cancer cells (167-170). Peptides can also be rationally 
designed to respond to acidity. Endocytosed pH-triggered peptides can release trapped molecules, 
such as drugs and siRNA, from endocytic organelles as the pH of the lumen acidifies during 
endosomal maturation (67, 78, 171, 172). This is a credible way for molecules to overcome the 
barrier of the cell membrane and enter the cytosol. Furthermore, there are several diseases that 
result in an altered pH balance, such as inflammation and cancer (35, 173, 174).  The local 
extracellular pH of cancer cells can be 0.5-1 pH units lower than their healthy counterparts due to 
altered glucose metabolism, vascularization, and induction of carbonic anhydrase IX, among other 
49 
 
factors (91, 175, 176). This process is accentuated by the local concentration of protons on the 
surface of cells, which results in a significantly more acidic pH than in the bulk microenvionment 
(177, 178). Using pH-sensitive peptides as a tool to target the plasma membrane of diseased cells 
can allow for higher targeting specificity of acidic diseased tissues compared to healthy ones (86, 
110).   
We have recently designed the synthetic pH-sensitive acidity-triggered rational membrane 
(ATRAM) peptide (100). ATRAM is a 34-amino acid peptide (sequence: 
GLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN) that interacts with lipid bilayers in a pH 
dependent manner.  In neutral/basic solution, ATRAM is unstructured, but in the presence of lipid 
bilayers, it partitions to the membrane surface. An acidic environment causes ATRAM to insert 
gaining helical structure, forming a transmembrane helix, as determined by standard and oriented 
circular dichroism(100). Insertion of ATRAM into the membrane is driven by protonation of the 
acidic glutamates, which increases the overall hydrophobicity of the peptide. Biophysical 
experiments showed that the membrane insertion midpoint is pH 6.5 (100). Such pH midpoint is 
higher than the pKa of the Glu side chain, however this is not surprising, as the hydrophobicity of 
the membrane can promote large changes in pKa (179, 180). Additional in vitro experiments 
showed that ATRAM associates with melanoma and lung cancer cells more efficiently in acidic 
environment than at neutral pH (100).  A recent study has shown that ATRAM has a high cancer 
therapeutic index in vitro (181). The therapeutic index was determined by comparing the efficacy 
of amanitin toxin labeled peptide in killing cancer cells at low and physiological pH. The higher 
therapeutic index indicated that ATRAM targeted cancer cells in a low pH environment more 
efficiently compared to a neutral pH environment. Furthermore, it also successfully targeted 
tumors in vivo, suggesting that ATRAM shows promise as a cancer therapeutics peptide (181).  
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To fulfill the promise of ATRAM as a therapeutic peptide, it is fundamental to understand the  
molecular mechanism ATRAM uses to interact with and insert into lipid membranes. Here, we 
determined the membrane topology by evaluation of the cellular uptake of fluorescently labeled 
ATRAM coupled to PEGylated liposomes. We furthermore present kinetics studies that indicate 
that the membrane insertion of ATRAM involves at least two intermediates. Binding and leakage 
experiments show that the interaction of ATRAM with lipid membranes is concentration 
dependent. Our results suggest that ATRAM forms oligomers at the membrane surface and the 
membrane interior. The degree of oligomerization importantly affects the interaction with the 
membrane. Renal clearance and enzymatic degradation are often challenging in therapeutic 
peptide design (182, 183). We investigated if this was the case, and observed that ATRAM was 
stable in circulation 4 hours after intravenous injection. However, how ATRAM is protected from 
degradation and excretion is not known. We have determined that ATRAM binds to serum 
albumin, which we propose can explain the prolonged circulation of ATRAM in mice.  The results 
of the SPECT/CT and biodistribution studies conducted in mice support this hypothesis.  
 
3.3. Experimental Procedures 
 
Preparation of liposomes. Stocks of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 
and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) 
(16:0 Liss Rhod PE) (Avanti Polar Lipids Inc., Alabaster, AL) were prepared in chloroform. 
Appropriate aliquots of lipids were dried with argon gas and then placed under a vacuum overnight. 
Unless stated otherwise, the dried lipid films were hydrated with 10 mM NaPi (pH 8.0), and large 
unilamellar vesicles (LUVs) were prepared with a Mini-Extruder (Avanti Polar Lipids, Inc.) 
through 100 nm polycarbonate filters (Whatman).  For the membrane orientation studies, loaded 
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liposomal formulation were prepared by standard physical extrusion method following the 
published literature(184). In detail, lipid mixtures of POPC/POPC-FITC (75:25) and 
POPC/POPC-FITC/DSPE-PEG2000 maleimide (75:20:5) molar ratio were mixed in chloroform 
and vortexed. The solvent was evaporated using nitrogen gas, and the lipid film was left in a 
vacuum chamber overnight. Dry lipid was hydrated with 1 mL of 10 mM phosphate-buffered 
saline (PBS) (pH 7.4) to the glass vials of lipids and agitated. Hydration time was ~0.5 hours with 
vigorous vortexing.  Multilamellar liposomes were obtained after resuspension, and were subjected 
to 10 freeze-thaw-vortex cycles. Unilamellar liposomes were finally obtained after extruding 20 
times through 100 nm polycarbonate filters. Samples were filtered before use by using a 200 nm 
filter. 
Labeling of peptides. For the membrane orientation studies, DSPE-PEG2000 was conjugated at 
the single cysteine present at the N- or C-terminus of ATRAM (Table 2). The molar ratio between 
DSPE-PEG2000-maleimide (2941.605 g/mol) to ATRAM peptide (3341.95 g/mol) was 
approximately 1 (500 nM) : 20 (1 mM). In a typical synthesis, peptide was mixed with DSPE-
PEG2000-maleimide in of methanol and stirred overnight at room temperature, and then passed 
through a Sephadex G-25 minicolumn (PD-10 columns; GE Healthcare Bio-Sciences, 
Marlborough, MA) to remove the unlabeled peptides. The size of liposomes was measured by 
dynamic light scattering (DLS) using a Malvern Zetasizer instrument with disposable cuvettes 
right after the extrusion of liposomes. The surface charge of the liposome was – 10 mV, and size 
was around 175 nm (Figure 7).  
For the biophysical experiments, reactive NBD, [N, N'-dimethyl-N-(iodoacetyl)-N'-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine] (Thermo Fisher Scientific, Inc., Waltham, MA) 
was conjugated to a C-terminal cysteine in a Cys ATRAM variant and pHLIP (Table 2).  For the  
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* Biophysics experiments  








Figure 7. Zeta potential (A) and size analysis (B) for ATRAM-functionalized PEGylated 




cell binding assay, Y-ATRAM (Table 2) was labeled at the N-terminus with 3-BODIPY-propanoyl 
-aminocaproic acid N-hydroxysuccinimide ester (BODIPY FL-X; Invitrogen, Carlsbad, CA). In 
all cases, free dye was removed by gel filtration through a PD-10 column, while labeled and 
unlabeled peptide were separated by reverse-phase HPLC (Agilent, Santa Clara, CA).  MALDI-
TOF (Bruker, Billerica, MA) was used to confirm labeling.  
Y-ATRAM was radiolabeled with 125I, by using chloramine T as the oxidizing agent.  The 
reaction was quenched by addition of sodium metabisulfite.  Radiolabeled ATRAM peptide was 
diluted in 0.1% sterile gelatin in PBS. Free radioiodine was removed through a PD-10 column 
equilibrated with 0.1% gelatin/PBS. Fractions containing the maximal radioactivity were 
collected. The product radiochemical purity was confirmed by SDS-PAGE and analyzed by 
phosphor imaging (Cyclone Storage Phosphor System, Perkin Elmer, Shelton, CT). 
Cellular uptake analysis by confocal fluorescence microscopy and fluorescence-activated cell 
sorting (FACS). The membrane topology of ATRAM was assessed by measuring cellular uptake 
with microscopy and flow cytometry.  Human breast cancer MCF-7 cells (ATCC no. HTB-22) 
were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin (all from Sigma) in 5% CO2 at 37 °C. Once the cells reached ~ 95% confluence, they 
were split (using 0.25% trypsin-EDTA, Sigma) into fractions and propagated or used in 
experiments. Cells were seeded at a density of 2 ×104 cells/well in 500 μL complete medium in 4 
well cell-view glass bottom culture dish (Greiner bio-One, Germany) for confocal microscopy or 
6-well plates for FACS. After culturing for 24 h, the cells were washed and the medium was 
replaced with fresh phenol red- and serum-free medium (pH 6.5 or pH 7.4) containing 10 µM 
FITC-labeled liposomes (L), PEGylated liposomes (PL), PEGylated liposomes-ATRAM Nt (PL-
AN) or PEGylated liposomes-ATRAM Ct (PL-AC), and incubated for 1 h. Finally, the medium 
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was once again replaced with fresh medium to remove any extracellular liposomes. Cells were 
imaged on an Olympus Fluoview FV-1000 confocal laser scanning microscope, with a 63× Plan-
Apo/1.3 NA oil immersion objective with DIC capability. Images were processed using the Fiji 
software(185). Uptake was quantified by FACS using a BD FACSAria III cell sorter (BD 
Biosciences, San Jose, CA) (10,000 cells/sample, gated on live cells by forward/side scatter and 
propidium iodide exclusion). Analysis was performed with the BD FACSDiva software. 
Stopped-flow fluorescence. The intermediates of the transition from the surface bound state of 
ATRAM to its transmembrane state was followed by stopped-flow fluorescence.  Lyophilized 
NBD-labeled ATRAM (ATRAM-NBD) was hydrated in 10 mM NaPi pH 8.0 and incubated with 
POPC vesicles for one hour at lipid-to-peptide molar ratios of 200:1, 400:1, or 600:1. The lipid-
peptide samples were mixed at a 1:1 volume ratio with 100 mM sodium acetate pH 3.6 (inserted 
state) or 100 mM sodium phosphate pH 8 (peripheral state) to reach a final peptide concentration 
of 0.1 μM.  Fluorescence spectra were recorded on a SX20 Stopped-Flow instrument (Applied 
Photophysics, Inc., Surrey, United Kingdom) with a 505 nm cut-off filter at 25°C. The excitation 
wavelength was set to 488 nm. The data of the peripheral state were subtracted from the inserted 
state to account for potential photo-bleaching and light scattering (186).  Subtracted data were 
analyzed with a three-exponential model using the following equation: 
Signal = −A1 × exp(−𝑘𝑘1 ×  x) − A2 × exp(−𝑘𝑘2 ×  x) − A3 × exp(−𝑘𝑘3 ×  x) +  Fo (3), 
where A is the amplitude of the signal, k is the rate constant, x is time, and Fo is the offset (186).  
Sulforhodamine B leakage assay. The membrane disruption behavior of ATRAM was monitored 
by sulforhodamine B leakage assay in liposomes. A dried POPC lipid film was rehydrated with 20 
mM sulforhodamine B (SRB) in 10 mM sodium phosphate pH 8. Large unilamellar vesicles were 
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prepared as described above but using 200 nm filters.  Non-encapsulated SRB was removed by gel 
filtration through a PD-10 column (GE Healthcare Life Sciences). A constant amount of peptide 
was added to the SRB-LUV suspensions at different initial concentrations to cover a range of 
peptide:lipid mole ratios. Samples with either 10 mM sodium phosphate pH 8 or 1.5% Triton X-
100 were prepared as controls. After a 1-hour incubation at room temperature, the pH was altered 
with 100 mM sodium acetate pH 4.1 or maintained with 100 mM sodium phosphate pH 7.5.  The 
samples were measured after an additional 1-hour incubation.  The change in fluorescence 
intensity was measured using a Cytation 5 microplate reader (Biotek Instruments, Inc., Winooski, 
VT) with an excitation wavelength of 550 nm and emission wavelength of 590 nm. SRB leakage 
was calculated with the following equation: 
% Leakage = 100 ×  (𝐹𝐹−𝐹𝐹𝑚𝑚𝑚𝑚𝑚𝑚)
(𝐹𝐹𝑚𝑚𝑎𝑎𝑚𝑚−𝐹𝐹𝑚𝑚𝑚𝑚𝑚𝑚)
  (4), 
where F, Fmax, and Fmin are the measured fluorescence intensities of SRB-POPC vesicles with 
peptide, Triton X-100, and buffer, respectively (187).   
NBD lipid binding assay. To determine the effect of peptide concentration on membrane affinity, 
the partition coefficient was determined at different peptide concentrations. Lyophilized ATRAM-
NBD was hydrated in 10 mM NaPi pH 8.0 and incubated with increasing concentration of POPC 
vesicles at a final peptide concentration range of 0.125 – 0.8 μM and identical ranges of lipid-to-
peptide ratio with a maximum of 500:1. The pH of the samples was changed with 100 mM sodium 
acetate pH 4 or 100 mM sodium phosphate pH 7.5. This was repeated with pHLIP-NBD with final 
peptide concentrations of 0.1375 μM and 0.55 μM. Fluorescence spectra were recorded at 25°C 
with excitation at 470 nm and an emission range of 520-600 nm, using a Cytation 5 imaging plate 
reader. Fluorescence data (F) were normalized to the highest value of each individual isotherm and  
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were fitted with: 




where Fo is the initial fluorescence intensity, ΔF is the change between the initial and final 
fluorescence intensity, [L] is the lipid concentration, Kp is the partition coefficient, and 55.3 is the 
molar concentration of water(188). Experiments with a fitting R-squared of less than 0.8 were not 
included due to poor fitting. All the normalized data of their respective conditions were overlaid 
and fitted using Eq. 5 to calculate the partition coefficient. 
pK determination. The effect of peptide concentration on the pK of insertion was assessed by pH-
titrations experiments. ATRAM-NBD was incubated with POPC vesicles at a 1:200 molar ratio 
and final peptide concentrations of 0.4 and 0.8 μM. The pH of the samples was adjusted 
accordingly with 100 mM buffers (sodium acetate, MES, HEPES, or sodium phosphate). 
Fluorescence emission spectra were acquired at the excitation wavelength of 480 nm. The 
excitation and emission slits were set to 3 nm. Measurements were performed on a Photon 
Technology International Quanta Master fluorometer (Edison, NJ).  Appropriate lipid backgrounds 
were subtracted in all cases. The data were analyzed following the fluorescence intensity at 525 





where Fa is the acidic baseline, Fb is the basic baseline, m is the slope of the transition, and pK is 
the midpoint of the curve. 
Serum albumin binding assay. To determine the possibility of ATRAM using serum albumin as 
a carrier molecule, a binding assay were performed. Human serum albumin (HSA, ≥96% purity, 
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Sigma-Aldrich) and ATRAM-NBD were prepared in PBS.  A constant concentration of peptide 
(0.4 μM) was added to a range of increasing concentrations of HSA (0.25-15 μM).  The peptide 
concentration was chosen from the results of the lipid binding assay. The selected concentration 
(0.4 μM) was the lowest concentration where the peptide concentration had no effect on the 
partition coefficient. The concentration range of HSA was picked due to the binding curve 
achieving saturation.  Fluorescence anisotropy was measured on Photon Technology International 
Quanta Master fluorometer at room temperature with the excitation and emission wavelengths set 
to 460 and 535 nm, respectively. The excitation and emission slits were set to 6 nm.  The 
dissociation constant (Kd) was determined using the following equation: 
< r >=< r >𝑏𝑏+ (< 𝑟𝑟 >𝑓𝑓−< 𝑟𝑟 >𝑏𝑏)
([L]+Kd+[P])−�([L]+ Kd +[P])2−4[L][P]
2[P]
   (7), 
where <r> is the measured anisotropy, <r>f and <r>b are the anisotropy for the free and the 
completely bound fluorescent ligand, respectively. [L] and [P] represent the total fluorescent 
ligand (ATRAM-NBD) and protein (HSA) concentration, respectively (189, 190).  
Vesicle transfer assay. The spontaneous transfer of ATRAM from human serum albumin to 
membrane vesicles was measured using a fluorescence transfer assay. Human serum albumin, 
POPC and ATRAM-NBD were prepared in PBS.  ATRAM-NBD was incubated with POPC or 
HSA for 1 hour with a final peptide concentration of 0.5 μM at pH 7.4. The final molar ratio of 
lipid to peptide was 250:1, while the molar ratio of HSA to peptide was 10:1. Additionally, POPC 
was added to the samples containing the peptide-HSA mixture and incubated for 1 hour. The final 
concentrations were kept constant. Fluorescence spectra were measured on a Photon Technology 
International Quanta Master fluorometer at room temperature with the excitation wavelength set 
to 460 nm, and the emission wavelength ranging from 490 to 630 nm. The excitation and emission 
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slits were set to 6 nm. Anisotropy values were measured on a Horiba Fluorolog-3 
spectrofluorometer (Edison, NJ) at room temperature with the excitation wavelength set to 460 
nm, and the emission wavelength set to 535 nm. The excitation and emission slits were set to 6 
nm. Appropriate blanks were subtracted. 
pH-dependent cell binding. To determine whether the addition of tyrosine had an effect on the 
pH-dependency of the peptide in cells, pH-dependent cell binding experiments were performed 
with Y-ATRAM.  H358 cells, obtained from ATCC, were cultured in a humidified incubator under 
5% CO2 in RPMI medium supplemented with 10% of Fetal Bovine Serum, 50 U/mL penicillin, 
50 μg/ml streptomycin (Invitrogen). Two days prior the experiment, cells were plated at a seeding 
density of 1 x 104 cells per well in a 96-well black collagen-coated plate (Corning, Corning, NY). 
The binding assay was performed by washing cells twice with PBS supplemented with 1 mM 
MgCl2 and 100 μM CaCl2 (PBS++) and incubating with 2 μM BODIPY labeled Y-ATRAM for 5 
min. After a 90 s incubation with PBS++ containing 10 mM dextrose (Sigma-Aldrich) at different 
pH values, cells were washed one time in the same pH buffer, and then fixed with 4% 
paraformaldehyde for 30 min. Fluorescence intensity at 488 nm was detected in a plate reader 
(Synergy 2, Biotek). The quantification analysis is a result of three independent experiments 
performed in triplicate. 
SPECT/CT imaging. To visualize the biodistribution of ATRAM in mice, SPECT/CT imaging 
was performed as described elsewhere (191).  Briefly, Balb/c mice from a colony maintained at 
UTMC, females between 8 and 12 weeks of age, mice (n = 3) were injected with ~5 µg of 125I-
ATRAM, ~80 µCi in the lateral tail vein.  The mice were euthanized after an uptake time of either 
1 h or 4 h by isoflurane inhalation overdose.  SPECT images were attained using an Inveon 
trimodality imaging platform (Siemens Preclinical Solution, Knoxville, TN). CT data were 
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obtained using an X-ray voltage biased to 80 kVp with a 500 mA anode current, with 4 x 4 binning.  
SPECT and CT images were visualized with the Inveon Research Workplace visualization 
software package (Siemens Preclinical Solution, Knoxville, TN).  
Tissue biodistribution measurements. To support the SPECT/CT data, biodistribution 
measurements were performed as described previously (191).  Briefly, from every mouse that was 
imaged with 125I-ATRAM, samples of heart, kidneys, intestines, spleen, liver, pancreas, and 
stomach were harvested post mortem.  Each sample was weighed, and the 125I radioactivity was 
measured using an automated Wizard 3 gamma counter (192) (1480 Wallac Gamma Counter, 
Perkin Elmer).   
Microautoradiography. Similar to the tissue biodistribution measurements, 
microautoradiography was performed to support the SPECT/CT data. Each tissue sample was 
fixed in 10% buffered-formalin and embedded in paraffin. Then, 6-μm-thick tissue sections were 
dipped in NTB-2 emulsion (Eastman Kodak), stored in the dark, and developed after a 4-day 
exposure.  Each section was counterstained with hematoxylin and eosin.  
Peptide stability in serum. To study the stability of the peptide in serum, a concentrated stock of 
ATRAM-NBD (300 μM) was diluted in fetal bovine serum for different times and incubated at 
37°C. ATRAM-NBD was separated from serum proteins using chloroform/methanol, and the 
solvents were dried, and resuspended in methanol for HPLC. We used a StableBond Analytical 
Agilent Zorbax 300 SB-C18 column on an Agilent 1200 series HPLC system (Santa Clara, CA). 
The gradient from solvent A (H2O + 0.05% TFA) to solvent B (methanol + 0.05% TFA) started 
with a 15 minute gradient from 5% B to 80% B followed by a 35 minute gradient from 80% B to 





Cellular studies of the orientation of ATRAM membrane insertion. The establishment of the 
TM helix of ATRAM requires only one peptide end to insert across the membrane. However, it is 
not known if the insertion has a preferred orientation. To determine the directionality of the 
membrane insertion of ATRAM, we developed an assay where either the Ct or Nt of ATRAM were 
conjugated to a large particle, which is expected to block membrane insertion through the that 
peptide end. Specifically, we conjugated either the Nt of ATRAM (PL-AN) or the Ct of ATRAM 
(PL-AC) separately to the PEGylated liposome (PL). We initially studied ATRAM insertion in 
MCF7 human breast cancer cells using fluorescence-activated cell sorting (FACS). We used 
fluorescent (FITC)-labeled lipids to detect any liposome attachment to the cells mediated by 
ATRAM. After cell incubation with PL-AN at neutral pH, most cells were not labeled, and only a 
small population was weakly fluorescent (Figure 8A). However, when the experiment was 
repeated at pH 6.5, a pH close to the extracellular acidity of tumors (33, 91), most cells were 
labeled and with higher intensity. Control experiments showed that use of PEGylated liposomes 
devoid of ATRAM (PL), or standard liposomes (L), did not induce significant labeling at either 
pH value (Figure 8C). When the experiment was repeated with ATRAM conjugated with PL at 
the other peptide terminus, PL-AC, weak cell labeling was obtained at either pH (Figure 8B). 
These results suggested that when the Ct of ATRAM is available to insert into membranes (PL-
AN), acidity-triggered cell insertion is observed. However, a basal insertion was also observed in 
all conditions when ATRAM was present. This observation suggested the presence of a secondary 
cellular incorporation mechanism, such as endocytosis. 
Next, the cellular uptake of the liposomes (L, PL, PL-AN and PL-AC) was investigated 




Figure 8. Membrane orientation of ATRAM insertion in cells. (A-C) Quantification of cellular 
attachment by fluorescence-activated cell sorting (FACS).  FACS analysis of MCF-7 cells treated 
with FITC-labeled PEGylated liposomes conjugated to (A) Nt (PL-AN) or (B) Ct (PL-AC) 
ATRAM at pH 6.5 or 7.4 were compared to background fluorescence of untreated controls. (C) 
Summary of the FACS data for MCF-7 cells treated with FITC-labeled liposomes (L), PEGylated 
liposomes (PL), PL-AC or PL-AN at pH 6.5 or pH 7.4. Mean values are shown ± S.D. Statistical 
analysis was carried out using the Student’s t-test (n = 3). *P < 0.05; **P < 0.001 compared with 
















after incubation for 1 hour at pH 6.5 or 7.4. In agreement with the FACS data, fluorescence was 
more intense in cells incubated with PL-AN compared to PL-AC at pH 6.5 (Figure 9F). In both 
cases, the fluorescence signal was observed at the plasma membrane but also in an intracellular 
distribution suggesting endosomal localization (Figure 8D). At pH 7.4, a weaker intracellular 
fluorescence signal was detected for both PL-AC and PL-AN (Figure 9C/E). Taken together, the 
cellular results suggested that i) the C-terminal end of ATRAM inserts into cell membranes in a 
pH-dependent fashion, and that ii) endocytosis is a secondary nonspecific cell incorporation 
mechanism, albeit weaker in our experimental conditions (Figure 9G).  
Membrane insertion kinetics. To gain needed insights on the membrane folding and insertion 
pathway of ATRAM, we completed stopped-flow fluorescence kinetic experiments in vesicles, 
where we monitored the transition of the peptide from the peripheral state to the transmembrane 
state (186). To do this, we incubated NBD-labeled ATRAM with POPC vesicles at neutral pH for 
one hour. Next, samples were rapidly mixed with acidic buffer (pH 4) to trigger the formation of 
the transmembrane state, and we followed the fluorescence intensity change of the 
environmentally sensitive NBD dye. We observed that the fluorescence signal increased rapidly 
to a maximum before decaying slightly, and then finally slowly increasing again (Figure 10A).  To 
establish the best fit for the stopped-flow fluorescence data, we used kinetic models with zero to 
two intermediate states. The two-intermediate model had the fewest intermediates that had uniform 
residuals (Figure 11). This suggested that the peptide insertion process has at least two intermediate 
states. These stopped-flow experiments were performed at 400:1 lipid-to-peptide mole ratio.  We 
repeated this experiment at a lower and higher lipid-to-peptide mole ratio (200:1 and 600:1).  When 
comparing the three rate constants, we noticed that the first rate constant was significantly affected, 




Figure 9. Membrane orientation of ATRAM insertion in cells. (A-F) Assessment of cellular 
uptake by confocal fluorescence microscopy.  Images of MCF-7 cells following incubation with 
FITC-labeled (D) liposomes or (E) PEGylated liposomes. Cells treated with FITC-labeled 
PEGylated liposomes conjugated to (F-G) PL-AC or (H-I) PL-AN of ATRAM at pH 7.4 and pH 
6.5, respectively, 1h. Scale bar = 10 µm. (G) Schematic description of the efficient internalization 
by PL-AN compared to PL-AC at the acidic peritumoral pH condition. PL-AN internalization is 






Figure 10. Kinetics of ATRAM-NBD insertion in POPC bilayers. (A) Insertion of ATRAM 
from the peripheral to the inserted state was followed by stopped-flow fluorescence (400:1 
lipid:peptide mole ratio). Curves were fitted to a three exponential model (Eq. 4), indicating at 
least 2 intermediates. (B) The three rate constants are shown as k1 (black), k2 (red), and k3 (blue). 
The experiment was repeated with 200:1 and 600:1 lipid:peptide mole ratios. Mean values are 











Figure 11. Averaged stopped-flow spectra of ATRAM in POPC upon rapid mixing at (A) 200:1 
(n = 4), (B) 400:1 (n = 4), (C) 600:1 (n = 3) lipid:peptide mole ratios. Below the fluorescence data 
are the residuals of the three different exponential (Top to bottom: Residuals of three exponential 
to one exponential model). The fitting of exponential model was only accepted if the residuals 
were fully uniform. Red lines in top panels correspond to three exponential fitting.  
A B C 
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decreasing the peptide density on the membrane (600:1), the first step occurred more rapidly. The 
peptide density here is describing the amount of available peptide for the total lipid area and does 
not refer to the fraction of peptide bound to the lipid. The observed density-dependence might 
reflect repulsion effects or changes in the oligomerization state of ATRAM. To investigate the 
later possibility, we performed additional biophysical studies over a range of ATRAM 
concentrations.  
Membrane leakage is dependent on the oligomerization state. To gain more information about 
the oligomerization of ATRAM at/in the membrane, we performed a sulforhodamine B leakage 
assay. The assay was carried out at a constant POPC concentration and a range of ATRAM 
concentrations (0.00325-1.7 μM). Decreasing the lipid-to-peptide ratio from ~26000:1 (0.00325 
μM ATRAM) to 200:1 (0.5 μM ATRAM) resulted in an increase in leakage at both low and high 
pH (Figure 12A). However, after 200:1 lipid-to-peptide ratio at the high ATRAM concentrations, 
the amount of leakage decreased at both low and high pH. We also represent the leakage as 
function of peptide concentration (Figure 12B). We observed significant leakage (defined as 
>10%), at 13nM ATRAM and pH 8, and 52 nM at pH 4. Leakage decreased once the peptide 
concentration was higher than 0.5 μM. The trend of SRB leakage at pH 4 was similar to pH 7.5; it 
increased until ~0.5 μM, then the leakage started to decrease (Figure 12B). This showed that lower 
ATRAM concentrations were required for maximum leakage, while at higher concentrations, 
where increased ATRAM oligomerization was expected, the interaction with the membrane 
changed. 
Affinity to lipid membranes is concentration dependent.   The partition coefficient (Kp) defines 
the relative affinity between the solution and the bilayer phase (187). To determine if the lipid 




 Table 3. Stopped-flow rate constants and amplitudes 









) A1 (a.u.) A2 (a.u.) A3 (a.u.) 
 200:1 1.65±0.21 0.32±0.07 0.03±0.01 1.20±0.16 -0.23±0.04 0.23±0.04 
400:1 2.28±0.11 0.31±0.03 0.03±0.003 1.55±0.25 -0.41±0.09 0.33±0.06 
600:1 3.17±0.40 0.32±0.09 0.02±0.002 1.19±0.33 -0.46±0.16 0.15±0.07 
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Figure 12. ATRAM concentration affects POPC membrane disruption.  (A) The fluorescence 
intensity of sulforhodamine B (SRB) encapsulated in POPC vesicles was monitored after the 
addition of ATRAM (0.0025− 2 mol %) at pH 7.5 (blue) and pH 4 (red). Complete leakage was 
achieved on addition of Triton X-100. Mean values are shown ± S.D. (n = 3). (B) shows the same 









binding experiments at two ATRAM concentrations (0.25 and 0.8 μM) at pH 4, corresponding to 
the transmembrane state. We observed that ATRAM bound more readily to POPC at 0.25 μM than 
at 0.8 μM (Figure 13A). When we systematically repeated the binding experiments over a range 
of peptide concentrations (0.125-0.8 μM) (Figure 14), we observed that at increasing ATRAM 
concentration, the Kp decreased more than 10-fold (note the logarithmic scale in Figure 13B) and 
finally leveled off around 0.5 μM.  A similar decrease in affinity was also observed at physiological 
pH. In ideal conditions Kp should not depend on the concentration of ATRAM. However, as the 
partition coefficient is changing with concentration of the peptide, the binding is considered 
nonideal, and the true partition coefficient cannot be determined (188, 193). Therefore, the 
reported partition coefficient will be referred to hereafter as the apparent Kp (Kapp) (188). As shown 
earlier at a single ATRAM concentration, the apparent partition coefficient was consistently higher 
in the transmembrane state (acidic pH) than the peripheral state (neutral pH) (100).  This result is 
not surprising as the four glutamates present in ATRAM would be protonated at pH 4, which 
increases the hydrophobicity and, in turn, the membrane affinity of the peptide. We wanted to 
investigate if a change in oligomerization could cause the Kapp changes observed at neutral pH.  To 
this end we repeated the experiment with pHLIP, which is monomeric at both acidic and neutral 
pH under our experimental conditions (194). We observed that pHLIP also showed higher POPC 
affinity at low concentrations, indicating that a factor other than a change in oligomerization state 
is responsible for the Kapp changes in ATRAM. This raised the possibility that the pK, which 
reports on membrane insertion, varies at different concentrations. To explore this possibility, we 
measured the pH-dependent change in the fluorescence intensities of NBD labeled ATRAM at two 
concentrations, 0.4 and 0.8 μM (Figure 15). The obtained pK values were 6.67 ± 0.12 and 6.66 




Figure 13. Peptide concentration affects the adsorption of ATRAM to POPC vesicles. (A) 
Representative POPC binding assay of ATRAM-NBD at pH 4 with final peptide concentrations 
of 0.25 μM (closed symbols) and 0.8 μM (open symbols). The fluorescence intensities were 
normalized to the maximal value. Curves were fitted to Eq. 5 to determine the partition coefficient 
(Kp). (B) Kapp varies as a function of ATRAM concentration at both acidic (red) and physiological 
pH (blue), which was also observed with pHLIP at physiological pH (black).  Mean values are 




Figure 14. Representative fluorescence emission spectra of ATRAM-NBD at 0.8 μM (A/D) and 
0.125 μM (B/E), at pH 4 (A-B) and pH 7.5 (D-E). Representative Kapp binding curves at pH 4 





µM due to poor signal. Our data suggested that oligomerization changes did not affect the steady- 
state pH-dependent membrane insertion of ATRAM. 
ATRAM binds to human serum albumin. One of the biggest challenges of therapeutic peptides 
injected intravenously is their rapid clearance from circulation due to renal filtration and 
proteolytic degradation (183, 195).  Notably, ATRAM is able to target tumors efficiently in mice 
(181). However, it is not known how the peptide is able to evade proteolysis and clearance. We 
hypothesized ATRAM might avoid those processes due to being protected by binding to serum 
albumin. To test this possibility, we measured the change in anisotropy of NBD labeled ATRAM 
in the presence of human serum albumin (HSA).  Upon HSA incubation, we observed a saturating 
increase in anisotropy, expected to result from a decrease in the tumbling rate of the HSA-bound 
fluorescent peptide.  From the resulting isotherm, we determined that ATRAM binds to HSA with 
an affinity (KD) of 1.13 ± 0.37 μM (Figure 16A).  This result suggested that albumin binding might 
be the mechanism ATRAM uses to avoid fast proteolysis and clearance in the blood stream.  
Our data suggest that when ATRAM is injected into the blood stream, it can use serum albumin 
as a temporary carrier until it reaches its target. However, to concentrate within tumors, the peptide 
would need to first unbind albumin to gain access to the membrane of cancer cells.  We performed 
a fluorescence assay to study if there was transfer of ATRAM from HSA to membranes (POPC 
vesicles) (Figure 16B) (196, 197). The assay used NBD as an environmentally sensitive probe that 
responds to the presence of water (198, 199).  The fluorescence intensity of NBD increases upon 
moving from a fully hydrated to a less polar environment, such as those in the HSA binding site 
or lipid membranes. When ATRAM-NBD binds to HSA, we observed an increase in fluorescence 
intensity compared to peptide in solution (Figure 16C). This agrees with the increase in anisotropy 




Figure 15. ATRAM concentration does not affect the insertion pK into POPC vesicles. 
Representative pH titration curves obtained by monitoring the fluorescence intensity changes of 
ATRAM-NBD at 525 nm (n = 4). The final concentrations of ATRAM were 0.4 μM (closed 






Figure 16. Lipid membranes compete with human serum albumin for ATRAM binding. (A) 
Representative binding curve of ATRAM-NBD to human serum albumin measured by 
fluorescence anisotropy. The curve shows the fitting obtained with Eq. 7 to determine the 
dissociation constant (KD). (B) Flow chart of the experimental steps to study the interaction of 
ATRAM with HSA and lipid vesicles. (C) Representative fluorescence spectra of ATRAM-NBD 
in solution (blue), bound to POPC (black), HSA (red), or bound to HSA with the addition of POPC 
(green). (D) Anisotropy values of ATRAM-NBD bound to POPC (black), HSA (red) or bound to 
HSA with the addition of POPC (green). Mean values are shown ± S.D. (n = 3-4; ***, p < 0.001; 
*, p < 0.05 from ANOVA). (E) Model of ATRAM (red) reversibly interacting with human serum 
albumin (dark grey; PDB 1AO6) and lipid membranes (light grey).  It is not known at which exact 









was bound to POPC vesicles. The differences in fluorescence intensity of ATRAM-NBD upon 
binding to either POPC or HSA likely occur due to the environment of the lipid being less solvated 
than the HSA binding site for ATRAM.  We studied next the potential transfer of ATRAM from 
HSA to membranes. Thus, ATRAM-NBD was preincubated with saturating levels of HSA, and 
then POPC vesicles were added. An increase in fluorescence intensity was observed compared to 
ATRAM-NBD in the presence of only HSA (Figure 16C), which suggested that ATRAM can 
unbind HSA to bind vesicles. However, since the fluorescence intensity was significantly lower 
than ATRAM-NBD in the presence of only POPC, this suggest that a fraction of ATRAM-NBD 
still remains bound to HSA in the presence of POPC vesicles at neutral pH.    
Additional anisotropy experiments were performed under the same conditions to confirm the 
findings (Figure 16D). ATRAM-NBD in the presence of HSA had a <r> value of 0.27 while in 
POPC vesicles the <r> value was 0.19. An intermediate anisotropy was observed after POPC was 
added to the ATRAM-NBD/HSA sample (<r> = 0.22). This confirms that ATRAM-NBD does 
interact with reversibly with HSA (Figure 16E), and in our experimental conditions, a fraction of 
ATRAM-NBD unbinds HSA in the presence of POPC. 
ATRAM biodistribution by imaging. Having shown that ATRAM binds to serum albumin in 
vitro, we wanted to study if it could correlate to a prolonged circulation half-life in vivo. Thus, we 
injected the peptide into wild type mice to confirm that the peptide does not undergo fast 
proteolysis and to study its biodistribution.  To this end, a variant of ATRAM was radioiodinated 
with iodine-125 (125I). Iodine-125 was incorporated into tyrosine residues under oxidative 
conditions (200, 201). As ATRAM does not have a tyrosine residue, we used an ATRAM variant 
(Y-ATRAM) where a leucine at the N-terminus was replaced with a tyrosine residue (Table 2).  
To ensure that the tyrosine residue does not affect the pH-responsive properties of ATRAM in 
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vitro, fluorescence was used to monitor the association of BODIPY-labeled Y-ATRAM with H358 
cells.  After a brief incubation with the peptide, cells were rinsed with solutions of differing pH, 
and the fluorescence signal was evaluated. Similar to WT ATRAM, Y-ATRAM associated with 
cells in a pH-dependent manner with stronger interactions in acidic environments compared to 
neutral ones (Figure 17) (100), validating the use of this peptide variant. 
The biodistribution of 125I-ATRAM in wild type (WT) mice was examined by SPECT/CT imaging. 
Figure 18A revealed a characteristic pattern of blood pool, with high activity in the liver and heart 
at both 1 and 4 hours post-injection (pi).  The liver and heart were both visible 4 hours pi, 
suggesting that there is still considerable 125I-ATRAM in the circulation.  Axial views, at both time 
points, were taken through the plane of the liver and demonstrate intense activity in this organ that 
persists for at least 4 hours pi. Similarly, high activity was observed in the thyroid and stomach.  
As radiolabeled peptide was injected intravenously, it would be eventually taken up by the kidneys 
and undergo catabolism and dehalogenation (202, 203). As shown in Figure 18A, this 
consequently led to the sequestration of radioiodine, and thus radioactivity of the thyroid and 
stomach were of equivalent intensity as the liver. At 4 hours pi, radioiodine levels decreased in the 
stomach due to emptying and gastrointestinal excretion of iodide.  In contrast, the thyroid gland 
activity became more intense due to increased accumulation of the 125I because radioiodine is 
organified and will remain permanently in the thyroid (204). Further examination indicated that 
there was no SPECT/CT evidence of accumulation of 125I-ATRAM at other organs and tissues. As 
we have shown in our biophysical experiments, lower ATRAM concentrations show higher 
membrane affinity and decreased membrane disruption. This could suggest that a lower 





Figure 17. Y-ATRAM-BODIPY binds to cells in a pH dependent fashion. Similarly to 





Figure 18. Distribution of 125I-ATRAM mice. (A) Whole body biodistribution of radioactivity 
by SPECT/CT in mice injected IV at 1 h and 4 h post injection shown from the coronal, sagittal, 
and axial views.  Radioactivity is false-colored red/yellow. (B) Tissue biodistribution of 125I-
ATRAM in wild type (WT) mice at 1 h and 4 h post injection.  Bars represent mean % injected 
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Tissue biodistribution of 125I-ATRAM radioactivity. Tissue radioactivity measurements were 
performed to quantify the amount of 125I-ATRAM in various organs and tissues. Activity in the 
kidneys was observed, as expected, since they are the major site of protein dehalogenation in mice.  
Similar to the SPECT images, the liver was found to have the highest levels of radioactivity at 
both 1 h (18% ID/g) and 4 h (10% ID/g) pi (Figure 18B). This suggests that 125I-ATRAM binds to 
components in the blood, which at some point is present at the liver.  One of these components is 
believed to be serum albumin, since our in vitro data show that ATRAM binds to HSA (Figure 
16). Furthermore, albumin, the most abundant plasma protein, at a concentration of 40-50 mg/ml 
(95, 205), is synthesized in the liver. The tissue biodistribution data also confirmed the presence 
and persistence of 125I-ATRAM in the heart, which represents the sum of activity in the 
myocardium and any blood trapped in the ventricle that was taken for tissue measurement. The 
spleen, pancreas, and intestines samples were all unremarkable relative to the liver, heart, and 
kidneys. Lungs were heavily trapped, as expected from the high levels of albumin in capillaries as 
well as in the pulmonary interstitium (206). 
Microautoradiography was used to study the microscopic distribution of 125I-ATRAM within 
organs and tissues. The presence of radiolabeled peptide is evidenced by the deposition of black 
silver grains in the autoradiographs. Corresponding to the imaging and tissue distribution studies, 
there was significant accumulation of 125I-ATRAM in the liver at both time points. The distribution 
was not focal, suggesting that there was no accumulation within cells. The distribution appeared 
diffuse but intense in the sinusoids and perivascular regions (Figure 19). The peptide was visible 
in the tubular lumen of the kidneys and associated with the vasculature and regions of the blood 
pool.  In addition to evidence of 125I-ATRAM in the blood pool, there was evidence of modest 
levels of ATRAM in the myocardium. These organs were juxtaposed to the spleen, where little or 
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Figure 19.  Microautoradiographs of tissue from WT mice injected IV with 125I-ATRAM peptide 
at 1 hour and 4 hours post injection.  Radiolabeled peptide is evidenced by the presence of black 
silver grains. Original magnification = 80x. 
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no activity was observed at either time point. Overall, the radioisotopic studies performed in mice 
agree with our hypothesis that ATRAM binds to a blood component as a carrier in vivo, which we 
suggest is albumin. 
Proteolytic cleavage of peptides often compromises their successful therapeutic application 
(207). We hypothesized that the binding of ATRAM to albumin might provide increased resistance 
to proteases. To evaluate this, we studied the stability of ATRAM in fetal bovine serum (FBS) at 
37°C. We observed no noticeable peptide degradation after 17 hours of FBS incubation (Figure 




Targeted therapies have the potential to provide more effective and selective treatment for cancer. 
However, to fulfill this promise we first need to understand the mechanism that molecules use to 
attain adequate pharmacodynamics and pharmacokinetics, as well as specific targeting of diseased 
cells. ATRAM was designed to use the acidity prevalent in aggressive tumors (35, 91, 174, 175) 
to trigger membrane insertion, which is useful for drug delivery and imaging applications (100). 
ATRAM exhibits promising properties for targeting tumors (181). In this work we carried out 
experiments that advanced the knowledge of the molecular basis of the action of ATRAM. While 
previous studies were performed with drugs conjugated at the C-terminus of the peptide (181), it 
was still not known whether membrane insertion occurs through this end or if the insertion is uni-
directional.   With flow cytometry and microscopy studies, we have determined that ATRAM does 
indeed insert into cells with its C-terminus in a unidirectional fashion (Figure 8 and Figure 9). 
However, we observed partially punctate patterns of intracellular fluorescence observed in the 
confocal microscopy images. This is often indicative of localization to endosomal compartments, 
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Figure 20. Serum stability of ATRAM conjugated with NBD.  (A) HPLC chromatograms 
obtained for free NBD dye and extracted ATRAM-NBD at t=0 h, and t=23 h are shown. Vertical 
axis shows the NBD absorbance (488 nm), and the horizontal axis the elution time in minutes (m). 
The HPLC gradient starts at 15 m and ends at 50 m.  (B) The ATRAM-NBD peak eluting at 26 m 
was quantified, and the normalized concentration is shown for different serum incubation times  
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and suggests that the peptide not only is inserted at the plasma membrane but is also partly taken 
up by endocytosis.  These studies also demonstrate that ATRAM can deliver larger molecules, in 
this case liposomes, to cells in a pH dependent manner. 
When ATRAM is in a membrane-adsorbed state, a pH decrease induces a conformational 
change that results in the formation of a transmembrane α-helix (100). However, it was not known 
if this process involved the presence of intermediate states. A simple two-state model cannot 
adequately fit the stopped-flow data shown in Figure 10A. Instead, a triple exponential equation 
is required to fit the data (Figure 11), indicating the presence of at least two intermediate states. 
The sign of the fluorescence intensity changes varied between different steps. A first process 
involved a fluorescence increase, as expected if the NBD reporter transitioned into a more 
hydrophobic environment. However, the second process involved an opposite intensity change. 
This observation suggests that the Ct of ATRAM, where NBD is conjugated, temporarily explored 
a less hydrophobic environment. The final step again involved a transition into a more hydrophobic 
environment, likely corresponding to the final formation of the transmembrane state. A similar 
scenario was observed for the pHLIP peptide, a monomeric pH-sensitive peptide that undergoes 
membrane insertion at acidic pH (110, 208). These observations suggest that pH-triggered peptides 
might contort into the membrane exploring different conformations before adopting the final 
transmembrane state (186). Interesting insights were obtained when the stopped-flow experiment 
was repeated at different peptide to lipid molar ratios, which allowed us to study the effect of a 
change in peptide density on the surface of the bilayer. We observed that the first process was 
significantly faster at low peptide densities (600:1 molar lipid-to-peptide ratio). The other two 
processes did not show a dependency on the peptide density (Figure 10B). However, the 
unambiguous identification of each process is challenging, in part because we cannot rule out that 
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other folding steps occur within the dead time of the instrument (first ~5 ms). Nevertheless, we 
can hypothesize that the first step should correspond to ATRAM lying at or close to the membrane 
surface. If this is correct, the dependency on peptide density would suggest that in the 
concentration range we studied, there was a change in the oligomerization state of surface-
adsorbed ATRAM. When larger oligomers are present on the membrane, this would result in a 
slower membrane insertion, probably because peptide-peptide interactions compete with peptide-
lipid interactions. 
To further probe ATRAM oligomerization, we studied if the concentration of ATRAM on the 
membrane surface could alter the permeability of the bilayer using an SRB leakage assay. We 
observed that leakage occurred at both neutral and acidic pH. The degree of leakage depended in 
both cases on the concentration of ATRAM (Figure 12A). This observation agrees with ATRAM 
forming oligomers both in the membrane-adsorbed and transmembrane states. In a recent study on 
aggregation of the antimicrobial peptide magainin II, Zou and colleagues found that cell 
membranes were disrupted less by large peptide aggregates when compared to smaller aggregates 
(209). The authors propose that magainin has to overcome a high self-interaction energy before 
the peptide interacts with a lipid membrane.  A similar behavior is proposed for ATRAM. We 
observed that leakage did not level off or continue to increase at ATRAM concentrations higher 
than 0.5 μM, but it resulted in a decrease in POPC vesicle disruption (Figure 12B).  Notably, 0.5 
μM is also the concentration where Wyatt et al. observed a break in the dose-dependency of 
ATRAM drug delivery in cancer cells (181). The decreased in leakage shown in Figure 12B might 
explain this observation, linking it to a change in ATRAM oligomerization that reduces the effi- 
cacy of drug delivery. 
We previously reported that ATRAM had minimal effect on membrane leakage of a different  
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fluorescent reporter, calcein (100). However, in light of our current understanding of ATRAM, 
that study was not comprehensive enough, since it was only performed at pH 8. While the leakage 
results yield information on the oligomerization of ATRAM, the destabilization ATRAM induces 
in the lipid bilayer is not enough to cause cell toxicity, as shown by two different reports (100). 
While we do not completely understand why ATRAM promotes more efficient leakage of SRB 
than calcein, as both molecules are similar in weight and are both anionic molecules, previous 
studies have shown that SRB is more prone to leakage with another peptide system (210).  
We observed that the apparent partition coefficient strongly decreased (Figure 13) at higher 
peptide concentrations at both low and physiological pH. To investigate the factors underlying the 
concentration dependency of the Kapp, we repeated the experiment with NBD-labeled pHLIP. 
While pHLIP shows overall less affinity to bind membranes than ATRAM, at higher 
concentrations pHLIP also reduced its lipid affinity. As pHLIP is a monomer in the experimental 
conditions used, this indicates that oligomerization changes are not responsible for the Kapp 
changes observed for ATRAM. Instead, the dependency of the Kapp value on lipid concentration 
reveals that our experiments were not in infinitely dilute conditions. Thus, the pattern of specific 
Kapp change we obtain is characteristic of anti-cooperative partitioning, typically observed where 
electrostatic repulsion hinders lipid binding at high peptide concentrations. This is not surprising 
since both ATRAM and pHLIP have a strong negative charge (-5 and -6, respectively) in their 
deprotonated peripheral state (188). For the pH 4 experiments, the peptides were incubated with 
POPC at pH 8 before acidification. The accumulation of negatively charged glutamates might 
result in electrostatic repulsion that carries into the electrically neutral transmembrane state.   
Overall, our results suggest that ATRAM forms oligomers of different sizes at different 
membrane densities. The smaller oligomers formed at lower densities insert faster into the 
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membrane (Figure 10), display significantly higher membrane affinity (Figure 13) and disrupt the 
membrane to a greater extent (Figure 12) than the larger oligomers. With the increased 
intermolecular interaction of ATRAM, there would be a higher energy cost for the peptide to 
interact with the membrane, which would slow down the initial phase of membrane insertion and 
reduce POPC affinity. However, both oligomer sizes show similar pH-dependency of membrane 
of insertion (Fig. S5), suggesting that the glutamate residues that control the insertion are in similar 
environments (211). 
Our mice data showed that ATRAM accumulates in blood-rich organs (liver and heart) (Figure 
18). Additionally, administration of the peptide did not adversely affect the test animals (data not 
shown). The biodistribution and SPECT/CT imaging data showed retention of radioactivity after 
4 hours in the heart and liver, indicating distribution throughout the circulatory system (Figure 18).  
The radioactivity of 125I was still detectable in organs after four hours, which is longer than for 
other peptides of comparable molecular weight (182, 200, 212, 213). We also observed that 
ATRAM was resistant to proteolytic degradation in FBS (Figure 20). Taken together, our data 
indicate that ATRAM might avoid some of the biggest challenges for therapeutic peptides, as it 
did not undergo quick proteolysis or clearance. A possible explanation for this phenomenon is that 
ATRAM is transported by a blood component. In fact, strategies have been explored to prolong 
the half-life of peptides by increasing their affinity to serum proteins, including conjugating 
peptides to ligands, such as PEG and fatty acids, (99, 182, 189, 214-216). Many hydrophobic 
molecules, such as fatty acids, cholesterol (97, 217), and hydrophobic therapeutic molecules (217-
221) are transported in the blood by binding to serum albumin, which prolongs their circulation 
time. Indeed, increasing albumin affinity is a common approach used to elongate the circulation 
half-life of biomolecules, including peptides (97, 214, 215).  Studies have confirmed that peptides 
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modified with fatty acids, such as liraglutide and insulin detemir, bind to serum albumin, and as a 
result have a prolonged circulation half-life compared to their non-modified counterparts (97, 215).  
The in vitro data shown in Figure 16A show that ATRAM binds to human serum albumin, 
suggesting that it uses this protein as a carrier in the blood stream, thereby explaining the long 
circulation time observed. The binding affinity (KD = 1.13 ± 0.37 μM) is slightly higher compared 
to a clinically used peptide, insulin detemir (4.16 μM) and other currently used drugs(97, 222). For 
example, phenylbutazone, warfarin, and penicillin G bind albumin with dissociation constants 
ranging from 1.4 μM (phenylbutazone) to 833 μM (penicillin G) (219-221). However, a binding 
affinity in the micromolar scale is generally considered weak binding (223). In our case, this could 
be beneficial, since too high of an affinity would preclude ATRAM unbinding HSA to target the 
membrane of cancerous cells. We devised an in vitro assay to study if this transfer could occur. 
We observed NBD intensity (Figure 16C) and anisotropy Figure 16D) changes, indicating that 
ATRAM interacted with lipid membranes after pre-incubation with serum albumin. However, the 
partitioning away from HSA into liposomes was not complete as expected from the HSA affinity. 
Specifically, at neutral pH the lipid affinity of ATRAM is lower (∆G= -7.7 kcal/mol) than for HSA 
(∆G= -8.1 kcal/mol), indicating that ATRAM favors HSA.  Furthermore, it has been shown before 
that HSA interacts with lipids (224-226). This raises the possibility that ATRAM might be directly 
transferred from HSA to POPC, forming a ternary complex under the experimental conditions of 
Figure 16C-D. Based on the low affinity of HSA to DMPC lipid vesicles (KD = 6.7 mM), only 
~3.5% of HSA would be bound to the lipid vesicles (227).  As a result, we expect that ATRAM 
must be in solution before binding to lipid vesicles. 
In the experimental conditions of Figure 16C-D, we worked with 4.2 x 1014 HSA molecules, 
and a significantly larger number of POPC molecules, 2.1 x 1016, which could be erroneously 
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interpreted as a larger affinity for HSA than POPC. However, the interaction of a peptide with 
lipids should not be considered as a chemical equilibrium. Instead, it is more appropriate to 
consider the interaction with the whole liposome surface (188). Based on the size of the liposome 
and the POPC area per lipid, we calculated that in our experimental conditions, the number of 
POPC liposomes was only 2.6 x 1011, a number significantly smaller than the number of HSA 
molecules. Within the limitations of our in vitro conditions, we consider the excess of HSA over 
the bilayer surface might not be too far away from the situation an HSA-bound ATRAM faces in 
the interior of a vein or capillary, where it would slowly partition into cells. Our results suggest 
that ATRAM could use HSA as a carrier and protector to travel through the bloodstream. At this 
point, ATRAM can potentially unbind HSA to migrate into the plasma membrane of cancer cells.   
Here we start to unravel the molecular mechanism ATRAM uses to target tumors. Achieving 
this ambitious goal requires understanding not only the mechanism of specific insertion in acidic 
membranes, but also the processes that allow for satisfactory biodistribution. However, in order to 
make ATRAM a strong therapeutic candidate, other key parameters need to be determined. To 
understand the insertion mechanism of ATRAM, the different oligomerization states of the peptide 
should be further characterized. We hypothesize that the reason ATRAM can assemble into 
different oligomers might be the presence of several GxxxG motifs, which often promote self-
assembly of transmembrane domains (228, 229).     
To advance the field of therapeutic peptides, the properties of targeted peptides, such as  
ATRAM, need to be further understood. This is required to optimize some off-target localization 
and the pH profile of ATRAM, which are currently under investigation in our laboratory. Here, 
we were able to gain new biophysical insights into the pH-dependent membrane interaction of 
ATRAM. We also showed that ATRAM can deliver PEGylated liposomes to breast cancer cells 
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in a pH-dependent fashion. We hypothesize ATRAM can target to the acidic microenvironment of 
tumors a wide range of nanoparticles, with probably the exception of positively charged 
nanoparticles, which might stablish deleterious electrostatic interactions with the charged 
glutamates in ATRAM. Furthermore, we also discovered that ATRAM interacts with a plasma 
protein, serum albumin, which might explain its promising biodistribution in mice. Different types 
of blood proteins bind to the surface of nanoparticles, forming a so-called protein corona (230). 
The protein corona is an important determinant of the specificity and efficiency for the uptake of 
nanoparticles. Our results strongly suggest that ATRAM-decorated nanoparticles will contain 
albumin in the inner layers of the corona. This might be a desirable property, since the ATRAM-
albumin affinity is weak, and this might preclude the formation of a stable “hard” corona (231). 
Overall, our studies provide new insights necessary to develop ATRAM for direct targeting of 
drugs to cells with an altered pH environment, such as tumors.  
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Chapter IV. The effect of phosphatidylserine on a pH-responsive peptide 








The acidity triggered rational membrane (ATRAM) peptide was designed to target acidic diseases 
such as cancer. The acidic environment of tumors drives the protonation of the glutamic acids of 
the peptide, leading to the insertion of ATRAM into the lipid membrane with its C-terminus. The 
cell membrane contains a variety of lipids. Compared to healthy cells, cancerous cells have the 
negatively charged phospholipid, phosphatidylserine (PS), exposed on the outer leaflet of their 
plasma membranes.   Here we use a reconstituted vesicle system to explore how phosphatidylserine 
influences the interaction of ATRAM with the plasma membrane of cancer cells. We observed 
that modifying the sequence of ATRAM at the N-terminus affected the lipid-peptide interactions 
further. The two new variants, K2-ATRAM and Y-ATRAM, displayed opposite behaviors in the 
effects of phosphatidylserine on the membrane insertion pK and lipid partitioning. For all three 
peptides, membrane leakage was reduced in the presence of the negatively charged lipids. Our data 
indicates that the effect of PS on the insertion pK is not only of electrostatic nature, but more 
complex than that. Here we try to understand how small changes to a peptide sequence can affect 
how the peptide will interact with a membrane to further the design of a therapeutic peptide that 





Efficacious targeting of specific molecular markers in cancerous tumors is limited by tumor 
heterogeneity and resistance acquired due to rapid mutation (232). Therefore, it can be 
advantageous to target instead an intrinsic tumor property, such as the extracellular acidity (233).  
Cancer cells preferentially metabolize glucose in the presence of oxygen (Warburg effect), 
resulting in an increase amount of secreted lactic acid (234). Combined with poor tumor perfusion, 
this leads to the accumulation of acidic metabolites and a reduction in the pH of extracellular 
matrix (33).  We developed the highly soluble acidity triggered rational membrane (ATRAM) 
peptide to target the acidic extracellular environment of tumors(100, 181). Biophysical and cellular 
experiments have shown that the membrane interaction of this highly soluble peptide is pH-
dependent. At physiological pH, ATRAM partitions to lipid membranes, but at acidic pH it inserts 
into the membrane as an alpha helix.  ATRAM has been able to deliver a cell-impermeable toxin 
into HeLa cells, as well as efficiently target solid tumors (181). The insertion pK of ATRAM in 
POPC vesicles was previously determined to be 6.5 (100). This pH is at the lower limit of tumor 
extracellular acidity (91, 235).  To address the need to target mildly acidic tumors, here we worked 
to tune the tumor-targeting properties by designing two variants with N-terminal modifications. 
The effect of positively charged amino acids and aromatic amino acids on the insertion of ATRAM 
was studied.  
Previous biophysical experiments studying the membrane interaction of ATRAM have been 
limited to use the phospholipid phosphatidylcholine (PC) headgroups in single component 
systems, more specifically 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) (100, 181).   
However, the lipid bilayer of the cell membrane is more complex as both leaflets contains a variety 
of lipids (236). We are particularly interested in one specific phospholipid, phosphatidylserine 
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(PS). PS represents approximately 10% of the phospholipids in the plasma membrane and remains 
sequestered in the inner leaflet of healthy cells (237). Compared to healthy cells that have 
asymmetric bilayers, cancerous cells can lose their asymmetry and as a result have 
phosphatidylserine on both leaflets of their plasma membranes (238, 239).  Unlike PC lipids that 
contain a zwitterionic head group, PS is a negatively charged phospholipid. ATRAM has a 
negative net charge at physiological pH; therefore, electrostatic repulsion can emerge between the 
negative charges of the peptide and the membrane of tumor cells. 
Here we show that the insertion pK of ATRAM did not change with increasing concentrations 
of the phosphatidylserine, but how the peptide interacted with the membrane was altered.  
Furthermore, the N-terminal modified variants interacted with the lipid membrane differently from 
ATRAM, though they both maintained their acidity-targeting properties. We looked into 
electrostatic interactions as a possible explanation for these different behaviors by performing 
additional experiments in the presence of NaCl.  By understanding how negatively charged lipids 
affect the insertion of ATRAM into membranes, we can continue to rationally fine-tuning the 
sequence of ATRAM and increase its efficacy to insert into cancer cell membranes. 
 
4.3. Experimental Procedures 
Preparation of liposomes. Stocks of POPC and POPS (Avanti Polar Lipids, Inc., Alabaster, AL) 
were prepared in chloroform. Lipids were dried flushing with argon gas and placed under a vacuum 
overnight to create lipid films. The resulting dried lipid films were hydrated with 10 mM sodium 
phosphate (pH 8.0) and extruded with a Mini-Extruder (Avanti Polar Lipids, Inc., Alabaster, AL) 
through 100 nm polycarbonate filters (Whatman, Maidstone, United Kingdom) to create large 
unilamellar vesicles (LUVs). 
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Peptide labeling. C-terminal Cys ATRAM and K2-ATRAM variants (Table 4) were conjugated 
to the environmentally sensitive dye NBD, [N, N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-
1,3-diazol-4-yl)ethylenediamine] (Thermo Fisher Scientific, Inc., Waltham, MA).   Y-ATRAM 
(Table 4) was labeled at the N-terminus with succinimidyl 6-n-7-nitrobenz-2-oxa-1,3-diazol-4-yl 
amino hexanoate (NBD-X SE; Anaspec, Fremont, CA). Free NBD dye was removed by gel 
filtration using a PD-10 column (GE Healthcare Life Sciences, Marlborough, MA), while labeled 
and unlabeled peptide were separated by reverse-phase HPLC (Agilent, Santa Clara, CA).  The 
purity of the conjugations was confirmed by MALDI-TOF (Bruker, Billerica, MA).  
pK determination. Peptides were prepared in 10 mM sodium phosphate pH 8.0 and incubated 
with vesicles POPC or POPC/POPS (molar ratio ranging between 95/5 and 80/20). After a 1-hour 
incubation at room temperature, the samples were pH-corrected with 100 mM buffers (sodium 
acetate, MES, HEPES, or sodium phosphate).  The final pH was measured after obtaining the 
fluorescence spectra. The molar lipid-to-peptide ratio was 200:1 with a final peptide concentration 
of 1 μM. The lipid-to-peptide ratio was changed to 150:1 for experiments studying the effect of 
salt due to the scattering effect of sodium chloride on the lipid vesicles.  The final sodium chloride 
concentration in those experiments was 150 mM. Fluorescence emission spectra was measured on 
a QuantaMaster fluorometer (Photon Technology International, Edison, NJ) with λex = 280 nm and 
λem = 310-400 nm. The emission polarizer was set to 90°, and the excitation polarizer was set to 0° 
to reduce the light scattering effect of liposomes (107). Appropriate lipid backgrounds were 








Table 4. Sequences of the ATRAM peptide and the variants 
Residues in red are the N-terminal modifications, while residues in blue are replaced with Cys 








where Fa is the acidic baseline, Fb is the basic baseline, m is the slope of the transition, and pKFI is 
the midpoint of the curve. 
The PS50 was determined by: 
𝐹𝐹𝑇𝑇 + (∆𝐹𝐹)  × (𝑥𝑥 /(𝑃𝑃𝑃𝑃50 + 𝑥𝑥)) (9), 
where Fo is the initial fluorescent signal, ΔF is the change in the fluorescent signal, and x is the 
molar percentage of PS.  
Circular dichroism. Peptides were prepared in 10 mM sodium phosphate pH 8.0 and incubated 
with POPC or POPC/POPS (9/1 molar ratio) vesicles. The pH of the samples was altered with 100 
mM sodium acetate pH 4 or 100 mM sodium phosphate pH 8 after a 1-hour incubation at room 
temperature. The final pH was measured after measuring the spectra. The lipid-to-peptide ratio 
was 200:1 with a final peptide concentration of 5 μM.  Appropriate blanks were subtracted. 
Measurements were performed on a Jasco J-815 spectropolarimeter (Easton, MD) at room 
temperature. Raw data were transformed to mean residue ellipticity according to  
[Θ] =  Θ
10𝑐𝑐𝑐𝑐𝑙𝑙
 (10), 
where Θ is the measured ellipticity in mdegree, l is the path length of the cuvette in cm, c is the 
peptide concentration in M, and N is the number of peptide bonds.  
Oriented circular dichroism. Lipid or lipid-peptide (50:1 molar ratio) films were resuspended in 
methanol and added onto two circular quartz slides (Hellma Analytics, Germany).  The slides were 
placed under vacuum for 24 hours to evaporate the solvent.  The samples on the slides were 
rehydrated with 100 mM sodium acetate pH 4 for 16 hours at room temperature at 96% relative 
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humidity.  The slides with the samples were placed on opposite sides of the OCD cell in a manner 
that would seal the cell.  This ensured that the saturated K2SO4 that filled the inner cavity of the 
cell would remain hydrated and constantly humidify the sample throughout the experiment.  The 
sample was recorded on a Jasco J-815 spectropolarimeter at room temperature.  Eight 45° angle 
intervals were measured to limit the artifacts caused by linear dichroism and then averaged for the 
final spectrum. Data were converted into mean residue ellipticity after lipid blanks were subtracted.  
The theoretical transmembrane and peripheral helix spectra was calculated as described by Wu 
and colleagues (122).   
NBD lipid binding assay. NBD labeled peptides were prepared in 10 mM sodium phosphate pH 
8.0 and incubated with various POPC or POPC/POPS (9/1 molar ratio) concentrations at a final 
peptide concentration of 0.2 or 0.5 μM. The lipid-to-peptide ratios were maintained over the two 
peptide concentrations. After a 1-hour incubation at room temperature, the pH of the samples was 
changed with 100 mM sodium acetate pH 4.05 or 100 mM sodium phosphate pH 7.5. Fluorescence 
spectra were measured on a Cytation 5 microplate reader (BioTek Instruments, Inc., Winooski, 
VT) with λex = 470 nm and λem = 520-600 nm.  Fluorescence intensities at 540 nm (F) were 
normalized to the highest value of each individual binding curve and were fitted with: 




where Fo is the initial fluorescence intensity, ΔF is the overall change in fluorescence signal, Kp is 
the partition coefficient, [L] is the concentration of lipids, and 55.3 is the molar concentration of 
water.  
Sulforhodamine B leakage assay.  Dequenching experiments were used to measure the release 
of sulforhodamine B (SRB) from POPC or POPC/POPS (9/1 molar ratio) vesicles. The dye was 
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encapsulated into large unilamellar vesicles (LUVs) by resuspending the dried lipid film with 20 
mM SRB and extruded with 200 nm filters. The SRB-LUV suspensions were purified with a PD-
10 column. A consistent volume of peptide at different initial concentrations was added to the 
SRB-LUV suspensions to extend a range of lipid-to-peptide ratios. Samples with either 10 mM 
sodium phosphate pH 8 or 1.5% Triton X-100 added instead of peptide were used as controls. The 
pH of the samples was adjusted with 100 mM sodium acetate pH 4.05 or maintained with 100 mM 
sodium phosphate pH 7.5 after a 1-hour incubation at room temperature. The change in 
fluorescence intensity was measured after an additional 1-hour incubation on a Cytation 5 
microplate reader with λex = 550 nm and λem = 590 nm.  SRB leakage was calculated with the 
following equation: 
% Leakage = 100 ×  (𝐹𝐹−𝐹𝐹𝑚𝑚𝑚𝑚𝑚𝑚)
(𝐹𝐹𝑚𝑚𝑎𝑎𝑚𝑚−𝐹𝐹𝑚𝑚𝑚𝑚𝑚𝑚)
  (12), 
where F, Fmax, and Fmin are the measured fluorescence intensities of SRB-LUV suspensions 
with peptide, Triton X-100, and buffer, respectively. A correction was applied to account for the 
change in SRB fluorescence caused by Triton X-100. 
The midpoint of leakage (SRB50) was determined by: 
𝐿𝐿𝑇𝑇 + (∆𝐿𝐿)  × (𝑥𝑥 /(𝑃𝑃𝑆𝑆𝑆𝑆50 + 𝑥𝑥)) (13), 
where Lo is the initial leakage percentage, ΔL is the increase in the leakage percentage, and x is the 
peptide:lipid molar ratio.  
Statistical analysis. Statistical analysis on pKFI and Kp was performed using the SPSSv25 software 
(IBM Analytics, Armonk, NY). Levene’s test was performed to determine the homogeneity of the 
variance. Multiple comparisons tests were chosen based on the homoscedasticity (Tukey) or 
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heteroscedasticity (Dunnett T3) of the data. Comparison of the pKFI values was performed using 




ATRAM variants. The molecular basis of the interaction of ATRAM with lipid membranes is 
poorly understood. To fill this void in knowledge we performed mutational analysis. However, so 
as not to disrupt the overall membrane interaction of the peptide, we did not mutate the inserting 
C-terminal end (240). Instead, we modified the N-terminus and created two variants, named K2-
ATRAM and Y-ATRAM (Table 4). We first performed studies at pH 8 where ATRAM is a 
surface-bound peptide, and then at pH 4 where ATRAM is a transmembrane peptide (100). 
Fluorescence emission and circular dichroism spectra both showed that the overall pH-
responsiveness of the peptides was maintained in both POPC and POPC/POPS (molar ratio = 9/1) 
lipid vesicles.  For the three peptides, the maxima of the fluorescence spectra blue-shifted more 
than 10 nm and was associated a large intensity increase when dropping the pH of the lipid 
environment (Figure 21 and Table 5). This indicates that upon acidification the single Trp (Table 
4) transitioned from a polar environment to a hydrophobic one. The CD spectra showed that the 
peptides were mostly unstructured in buffer and lipid vesicles at pH 8, but they formed alpha 
helices in lipid vesicles at pH 4 (Figure 22). These results were expected as the peptide pH-
responsive properties are driven by the protonation of the four glutamic acid residues present in 
all peptides and also because we did not alter the inserting C-terminal end.   
Oriented circular dichroism (OCD) was performed to study the helical orientation of the 
peptides with respect to the plane of the bilayer.  If a helical peptide forms a surface-bound helix,  
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Figure 21 The peptides interact with the lipid membrane in a pH dependent manner. 
Representative intrinsic tryptophan fluorescence spectra of ATRAM and the variants in the 





Table 5. Fluorescence spectral maxima of the acidic and basic baselines 
 
ATRAM (nm) K-ATRAM (nm) Y-ATRAM (nm) 
POPC acidic  327.3 ± 0.7 329.7 ± 1.2 324.5 ± 2.9 
POPC basic 341.1 ± 2.3 342.1 ± 2.1 343.9 ± 3.6 
POPC/POPS acidic 330.8 ± 0.8 320.2 ± 1.7 320.5 ± 1.9 
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Figure 22. The peptides changed in secondary structure in a pH dependent manner. CD 
spectra of ATRAM and the variants in solution at pH 8 (black) and in the presence of POPC (A) 
and POPC/POPS (9/1) (B) vesicles at pH 4 (red) and pH 8 (blue). 
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 the spectrum would show two clear minima at ∼205 and ∼222 nm, while the spectrum of a TM 
helix would have a single broad minimum at ~225 nm.  Our experimental data indicate that all 
peptides adopt a TM orientation at pH 4 in both lipid compositions (Figure 23). Theoretical 
oriented circular dichroism (OCD) curves in POPC vesicles were shown along the measured 
curves of the peptides to highlight the orientation of the variants.  The variation between the 
theoretical curves of the different peptides arises from the fact that the theoretical curves depends 
on the fractional helicity of the peptides (122, 241).  
pK of insertion. To determine the pKFI of insertion of the ATRAM variants, we followed the 
changes of the intrinsic tryptophan fluorescence intensities of the emission spectra as the pH is 
decreased from pH ~8 to pH ~4 (Figure 24)  (186).  Compared to ATRAM (6.20 ± 0.15), the pKFI 
of Y-ATRAM (6.27 ± 0.12) did not change significantly in experiments performed with POPC 
vesicles.  However, with K2-ATRAM, we observed a large acidic shift (5.42 ± 0.14).  We studied 
if similar results were observed when PS was present in the vesicles. Over a range of PS levels, 
the changes in pKFI of insertion differed between the three peptides (Figure 25 and Figure 26). 
ATRAM did not have a significant difference in its pKFI with the addition of PS in the lipid 
vesicles. However, there was a different and opposite behavior observed for K2-ATRAM and Y-
ATRAM. The presence of PS resulted in an increase in the pKFI of K2-ATRAM and a decrease in 
the pKFI of Y-ATRAM.  The effect on the pKFI was seen at low concentrations of PS as the PS50 
was 1.89 and 0.45 for K2-ATRAM and Y-ATRAM, respectively. The PS trend that was observed 
with Y-ATRAM also occurred previously with pHLIP, a model pH-sensitive membrane peptide 
(90).  For pHLIP, this decrease in pKFI was due to electrostatic interactions between PS and pHLIP 
as Coulombic interactions were screened with NaCl.  To study whether this was also the case for 
the ATRAM peptides, the pKFI was determined in the presence of 150 mM NaCl (Figure 25 and 
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Wavelength, nm  
Figure 23. The ATRAM peptides adopt a TM conformation at low pH.  (Top) Oriented circular 
dichroism spectra of the peptides (black) in hydrated stacked POPC bilayers. The dark grey and 
light grey lines correspond to theoretical OCD spectra for TM (dark grey) and surface-bound (light 
grey) helical peptides, respectively. (Bottom) Oriented circular dichroism spectra of the variants 
in hydrated stacked POPC/POPS (9/1). Theoretical curves were not generated due to uncertainties 
in the amount of peptide deposited on the quartz slides.  
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Figure 24. Representative pH titration curves of ATRAM and the variants. The pKFI of each 
peptide in POPC was determined as the midpoint of the change in the peptide intrinsic fluorescence 
intensities.   
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Figure 25. The effect of POPS and NaCl on the pKFI of ATRAM and the variants. (A) 
Increasing concentrations of PS results in a different trend for each ATRAM variant. (B) Effect of 
the addition of NaCl on the pKFI. Mean values are shown ± S.D. (n = 3-6), *p<0.05, 
**p<0.01,***p<0.001, NS = no significance.  
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Figure 26. Representative pH titration curves of ATRAM and the variants. The pKFI of each 
peptide was determined by following the change in the peptide intrinsic fluorescence intensities in 
POPC/POPS (9/1) (A/C) and POPC (B) as a function of pH in the absence (A) and presence (B/C) 
of 150 mM NaCl.    
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Figure 26). For ATRAM, the pKFI of both lipid conditions decreased compared to the values 
obtained in the absence of NaCl. This was also observed for Y-ATRAM; furthermore, the 
difference in pKFI values between the two lipid conditions was no longer observed.  However, pKFI 
of K2-ATRAM behaved differently. Specifically, it only decreased in liposomes with POPS but 
not for POPC only liposomes. Similar to Y-ATRAM, the difference in pKFI between POPC and 
POPC/POPS vesicles was lost in the presence of NaCl.  Furthermore, the pKFI in the presence of 
NaCl was still different than the other two peptides.  Titrations in the presence of NaCl were 
performed with a lipid-to-peptide ratio of 150:1 instead of 200:1 due to scattering effect of the 
lipid. There was no significant difference in the insertion pK of ATRAM in POPC vesicles at 150:1 
and 200:1 lipid-to-peptide ratios in the presence of 150 mM NaCl (Figure 27). To unravel the 
causes for the different effect of PS on the three ATRAM peptides, we performed additional 
studies. 
Partition coefficient. We have previously reported that the POPC affinity of ATRAM is higher 
at acidic pH than neutral pH as a consequence of the increased hydrophobicity resulting from the 
protonation of the glutamic acids (240). This was also observed for the ATRAM variants (Figure 
28). Interestingly, the effect of PS on the partition coefficient at acidic pH mirrors the trends seen 
in the pKFI as the Kp did not change for ATRAM, increased for K2-ATRAM and decreased for Y-
ATRAM.  Previously, the binding of ATRAM to the lipid membrane was considered nonideal as 
the partition coefficient depended on the peptide concentration, and thus the Kp is in reality an 
apparent Kp (240). Here we show that this was also true for all the variants in both lipid 
composition as we repeated the binding assay at a lower peptide concentration (Figure 29 and 


























Figure 27. Overlay of pH titration of ATRAM in POPC vesicles at 150:1 (open symbols) and 
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Figure 28. Kp of ATRAM and the variants. Partition coefficients of the peptides in the different 











Figure 29. The effect of POPS on the Kp of ATRAM and the variants. Partition coefficients of 
the peptides in the in different conditions. Mean values are shown ± S.D. (n = 3-4). *p<0.05, 
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Figure 30. Representative binding isotherms for ATRAM, K2-ATRAM, Y-ATRAM to POPC and 






Leakage. ATRAM oligomerizes on the membrane of POPC vesicles (100). Membrane disruption 
often results from peptide oligomerization (242). Next, we studied the effect of the peptides on 
leakage to gain insight into peptide oligomerization. We performed SRB leakage assay in POPC 
and POP/POPS (molar ratio = 9/1) vesicles (Figure 31), where SRB dequenching occurs as it is 
released. ATRAM and Y-ATRAM seemed to disrupt the POPC membrane similarly. ATRAM 
observed similar leakage at low and neutral pH, but the leakage midpoint (SRB50) saw a three-fold 
decrease at low pH compared to neutral pH (0.06 vs. 0.19, respectively). This trend was also 
observed for Y-ATRAM (SRB50 = 0.03 vs. 0.10).  However, K2-ATRAM had the least amount of 
leakage in the surface-bound state and a large difference in amount of leakage between the two 
states. Similar to ATRAM, the SRB50 was lower for the inserted state (0.17) compared to the 
surface-bound one (0.72). Unlike ATRAM and Y-ATRAM, the highest amount of peptide 
concentrations was required to acquire maximum leakage.  With the presence of PS in the vesicles, 
there was less leakage observed with K-ATRAM. The main difference for ATRAM and Y-
ATRAM was that they lost their property of needing lower peptide concentrations for maximum 
leakage. The SRB50 increased with the addition of PS for all three peptides in both pH 4 and 7.5 




In this work, we studied how ATRAM was affected by the presence of PS in the membrane. 
We also developed two N-terminal variants. Fluorescence and circular dichroism confirmed that 
the peptides maintained their pH-sensitive properties. Furthermore, OCD experiments showed that 
the peptide acquired a TM confirmation at low pH.  The OCD spectra of the peptides in 














Figure 31. Membrane leakage studies.  Dequenching of sulforhodamine B (SRB) encapsulated 
in POPC (A) and POPC/POPS (9/1) (B) vesicles was monitored after the addition of peptide 
(0.0025− 1 mol %) at pH 7.5 (blue) and pH 4 (red/orange). Complete leakage was achieved on 





charges of PS repelled each other (243), making it harder for lipid bilayers to stack on top of each 
other on the quartz slide, reducing the overall signal. 
Here, the pKFI of ATRAM was determined to be 6.2. However, the  previously published 
insertion pK value of ATRAM in POPC was 6.5 (100).  This value was determined by following 
the shift of the fluorescence spectral maximum over a pH range, while the new value was 
determined by following the changes of the intrinsic tryptophan fluorescence intensities. It has 
previously been shown for pHLIP that different methods of spectral analysis resulted in different 
pK values as each method reported on a different intermediate of the peptide’s transition into the 
membrane (186).  Previous stopped-flow fluorescence data showed that ATRAM undergoes at 
least three states when transitioning from the peripheral state to the TM state (240). This result 
suggests that the different pK values of ATRAM might be associated with a different 
conformational intermediate. 
The decrease in insertion pK of K2-ATRAM in POPC vesicles compared to ATRAM and Y-
ATRAM indicates that there was a need for more acid for the peptide to be able to insert as a result 
of the addition of the two basic residues. The interaction with the membrane defining the pKFI was 
electrostatic for ATRAM and Y-ATRAM, but this was not the case with K2-ATRAM since there 
is no change in pKFI with the addition of NaCl. As tumor cells have PS exposed on the outer leaflet 
of their cell membranes, we studied the effect of PS on the interactions of the peptides with 
membranes.  Interestingly, with the addition of PS in the vesicles, the two variants had opposite 
trends.  The increase in K2-ATRAM’s insertion pKFI is expected to resort from to favorable 
interactions with the negative charge of PS. This time the addition of NaCl also resulted in a 
decrease in pKFI, indicating that the main interaction with PS are electrostatic for all peptides. 
However, the NaCl experiments were performed at a lower lipid-to-peptide ratio (150:1 vs. 200:1). 
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While the pKFI did not differ for these two ratios (Figure 27), we cannot rule out that any effects 
from working at non-saturating conditions at pH 7.5, particularly for Y-ATRAM (Figure 30).  
Unlike Y-ATRAM, the pKFI of ATRAM and K2-ATRAM observed a different trend compared 
to pHLIP with the addition of PS. This result indicates that pKFI is not controlled by a simple 
electrostatic process (90). For pHLIP, it is believed that the decrease in membrane insertion pK for 
PS suggested that the protonatable residues are more hydrated (90). This would have resulted from 
the peptide having a shallower position on the membrane surface due to the negatively charged 
lipids and exposing the sidechains of the protonatable residues to the aqueous environment.  The 
spectral maximum of the C-terminal Trp is sensitive to hydration, and then it reports the membrane 
depth (Table 5). The Trp is surrounded by three of the four Glu. However, we did not observe a 
good correlation between the Trp hydration and the pKFI.  Here we hypothesize that the glutamate 
at position 12 (E12) affected the insertion pKFI that resulted from the modifications at the N-
terminus. E12 is the glutamate that is closest to the N-terminus but also the furthest from the Trp. 
Integration of the data of Table 5 and Figure 25A allows us to propose a working model (Figure 
32). W26 and E12 of ATRAM maintained a similar position on POPC membranes, resulting in no 
changes in the pKFI.  The polar lysines of K2-ATRAM does not favorably interact with the 
hydrophobic membrane, thus it pulls the N-terminal region, including E12, away from the 
membrane, resulting in a much lower pKFI (211). As ATRAM did not observe changes in its pKFI 
and spectral maximum with the presence of POPS, it is assumed that E12 and W26 maintained a 
similar position in both POPC and POPC/POPS membranes. For K2-ATRAM, the N-terminal 
interacted with the negative charges of PS due to the positive charges on the lysines. This brought 
E12 closer to the membrane, thus increasing the pKFI in the presence of PS. Y-ATRAM observed 




Figure 32. Schematic of the surface-bound state of the ATRAM peptides. The proposed 
locations of E12 and W26 residues are shown in green and blue, respectively, while the modified 
residues at the N-terminal are marked in pink. The two Lys are represented as a single sphere. The 





surface of negative electrostatic potential that binds to cations through electrostatic interactions 
(244). In our case, we can hypothesize that the interaction of the tyrosine and the negatively 
charged PS resulted in an electrostatic repulsion. This led to E12 be more exposed to the aqueous 
environment and decreasing the insertion pKFI in the presence of PS. Figure 32 only shows the 
proposed location of E12 and W26 in the surface-bound state as we do not assume that the TM 
state affected the changes in the pKFI. The Kp data at acidic pH correlate with the pKFI (Figure 25 
and Figure 26). The increase in affinity in the presence of POPS that was observed with K2-
ATRAM was probably due to favorable electrostatic interactions of the positively charged Lys and 
the negatively charged PS, while the opposite of seen with Y-ATRAM. The surface of negative 
electrostatic potential of Tyr probably resulted in non-favorable interactions with the negatively 
charged lipids and thus decreasing the binding affinity.  
While the peptides resulted in the leakage of SRB, we have shown before that the disruptions 
caused by ATRAM are not significant to cause cell death in cultured cells (100). SRB is a relatively 
small molecule (MW = 558.6 Da), indicating that the effects on the lipid membrane are small. 
Moreover, we previously reported that ATRAM had little effect on membrane leakage of calcein, 
while SRB observed a higher amount of leakage compared to calcein (100, 240). This corresponds 
to a previous report that SRB is more disposed to leakage with another peptide system (210). We 
have previously proposed that the concentration dependent leakage resulted from the need of 
ATRAM to overcome a high self-interaction energy before interacting with the POPC membrane 
as ATRAM oligomerizes (240). A similar explanation is proposed for Y-ATRAM. However, this 
property was lost in POPC/POPS liposomes and in K2-ATRAM.  The data suggest that 
oligomerization changes do not explain the differences.  
The pK of insertion of the variants still remained lower than the pH of the extracellular matrix 
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of tumor cells (pH 6.4–7.0) (36, 233), though the local pH at the membrane surface that would 
drive the peptide insertion is significantly more acidic that the bulk microenvironment (177, 178).  
However, K2-ATRAM did observe a higher affinity to membranes with PS. Furthermore, the 
presence of small amounts of PS rapidly increases the pKFI. These characteristics are important as 
it suggests that K2-ATRAM might display an increased specificity for tumor cells.  Y-ATRAM is 
expected to be the least effective cancer targeting peptide variant since its pKFI decreases and its 
partition coefficient is much lower when exposed to PS headgroups compared to POPC only 
vesicles. We will use the observations from these experiments to fine-tune the sequence of 
ATRAM as a specific therapeutic agent for acidic diseases such as solid tumors. 
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5.1. Conclusions  
Currently, therapeutic peptides are in high demand as they can improve the low accumulation 
of nanoparticles and drugs at tumor sites (157).  By attaching the nanoparticle or drug to a peptide, 
the peptide can improve their stability and tumor targeting specificity and efficiency.  As peptides 
are made up of amino acids, their properties can be easily altered to make it highly specific to its 
target. Many different tumor targeting peptides have been designed to target the properties of 
tumor cells, such as increased cell receptors or the presence of negatively charged lipids on the 
outer leaflet of the plasma membrane. In these cases, the sequence of the peptide would include a 
specific motif to bind to the cell receptor or a high number of positive charged amino acids to 
interact with the negatively charged lipid headgroups (21, 57). Another cancer cell property that 
can be targeted is the acidic extracellular matrix as cancer cells have an extracellular pH that is 
0.5-1 pH unit lower than healthy cells (36).  As glutamates, aspartates, and histidines have 
sidechains that are protonatable, including these amino acids into the peptide sequence can provide 
it pH-sensitive properties.  In this work, we have rationally designed and characterized a novel 
class of pH-responsive peptides, ATRAM.  
Biophysical and cellular experiments have been performed to show that the acidity-triggered 
rational membrane peptide can exist as a surface-bound or transmembrane peptide depending on 
the pH of the lipid environment.  The highly soluble peptide partitions onto the membrane as a 
primarily random coil structure at physiology pH and will fold into the membrane as a TM α-helix 
at acidic conditions. This structural change stems from the protonation of the four glutamic acids 
present in the peptide sequence. ATRAM also maintained its pH-responsiveness in two different 
cultured cancer cell lines. What makes ATRAM stand out in the diverse pH-sensitive peptide 
group is that ATRAM was not designed to and does not induce membrane pore formation. 
123 
 
Furthermore, its pK of insertion into lipid vesicles is higher than the other pH-sensitive peptides 
and closer to the range on mildly acidic tumors.  
We furthered the understanding of ATRAM’s insertion into lipid vesicles with fluorescence 
microscopy and more biophysical experiments. It was determined that the peptide inserts into the 
membrane in a primarily unidirectionally manner with its C-terminus across the plasma membrane. 
Moreover, this data confirmed that ATRAM is able to deliver large molecules to the cell membrane 
in a pH-dependent manner. We have also shown with kinetics experiments that the first observable 
intermediate formed when the peptide transitions from surface-bound to TM state is dependent on 
the peptide density on the surface of the bilayer while the other two transitions did not. The slower 
occurrence of the intermediate is believed to be related to the oligomerization state of ATRAM.  
Leakage and binding studies confirmed that the membrane interactions of the peptide are 
oligomerization and concentration dependent.  Furthermore, our data showed that the interaction 
of ATRAM with human serum albumin is potentially the reason why the peptide exhibits an 
extended bloodstream circulation in vivo. The abundant protein probably shielded the peptide from 
proteases once injected into the bloodstream. The fact that ATRAM was able to avoid immediate 
degradation leverages its ability to be used as a therapeutic molecule as proteolysis is a common 
downfall of peptides (245).  
ATRAM has only been studied interacting with membranes composed of PC phospholipids. 
However, the plasma membrane is a diverse system that contains a variety of additional 
phospholipid head groups, including PS. A normal cell actively keeps PS in the inner leaflet and 
away from the extracellular environment. However, this lipid asymmetry is lost in cancerous cells 
(239). ATRAM’s interaction with the lipid membranes changed with the addition of the negatively 
charged lipid. While the pK of insertion did not change, the binding and the membrane disruption 
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effects were affected. Moreover, N-terminal modification were made to generate two new variants, 
K2-ATRAM and Y-ATRAM.  Unlike ATRAM, these two variants did observe opposite trends in 
the insertion pK in addition to changes to their lipid binding and membrane disruption effects. We 
hypothesize that the differences on the insertion pK resulted from changes to the environment of 
E12, the glutamate closest to the N-terminal. This work shows that with the right modifications, 
an ATRAM variant can effectively target tumors without excluding mildly acidic tumors.  
Overall, my work emphasizes the ability of the ATRAM peptide class to be established as a 
therapeutic molecule for cancer and other diseases that lead to acidic tissues. The targeting abilities 
can be enhanced by continuing to rationally fine-tune the sequence of ATRAM.  
 
5.2. Future Directions  
We have only started to study the potential of ATRAM. Many more variants can be created and 
investigated for either lipid-protein interaction studies or therapeutic studies. The three variants 
studied here behaved differently in a more intricate lipid system.  It would be interesting to 
continue to study these properties and see how single modifications can affect lipid-protein 
interactions or even how it can affect self-interactions.  Furthermore, these peptides will currently 
target moderately acidic tumors, which is not the most ideal in terms of cancer targeted therapy as 
they would exclude mildly acid tumors and early stage tumors (36).  A study has shown that 
replacing a glutamic acid into the ATRAM sequence will lower the insertion pK (data not shown). 
Perhaps by removing a glutamate or by moving one up or down the sequence can change the 
insertion pK to a desired range in the presence of PS, while maintaining its ability to avoid 
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